Assessment Report On Ginkgo Biloba L., Folium D
Assessment Report On Ginkgo Biloba L., Folium D
Assessment Report On Ginkgo Biloba L., Folium D
EMA/HMPC/321095/2012
Committee on Herbal Medicinal Products (HMPC)
Pharmaceutical form(s)
Rapporteur
Dr Jacqueline Wiesner
Assessor(s)
Eva-Maria Eibl
Note: This draft assessment report is published to support the release for public consultation of the
draft Community herbal monograph on Ginkgo biloba L., folium. It should be noted that this document
is a working document, not yet fully edited, and which shall be further developed after the release for
consultation of the monograph. Interested parties are welcome to submit comments to the HMPC
secretariat, which the Rapporteur and the MLWP will take into consideration but no overview of
comments received during the public consultation will be prepared in relation to the comments that
will be received on this assessment report. The publication of this draft assessment report has been
agreed to facilitate the understanding by interested parties of the assessment that has been carried
out so far and led to the preparation of the draft monograph.
7 Westferry Circus Canary Wharf London E14 4HB United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051
E-mail info@ema.europa.eu Website www.ema.europa.eu
European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Introduction ....................................................................................................................... 4
1.2. Information about products on the market in the Member States ............................... 5
1.3. Search and assessment methodology ................................................................... 30
2. Historical data on medicinal use ...................................................................................... 30
3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal
preparation(s) and relevant constituents thereof ........................................................... 33
3.1.1. Primary pharmacodynamic................................................................................ 33
3.1.2. Secondary pharmacodynamic ............................................................................ 34
3.1.3. Safety pharmacology ....................................................................................... 35
3.1.4. Pharmacodynamic interactions .......................................................................... 37
3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
preparation(s) and relevant constituents thereof ........................................................... 37
3.2.1. Absorption ...................................................................................................... 37
3.2.2. Distribution ..................................................................................................... 37
3.2.3. Metabolism ..................................................................................................... 37
3.2.4. Elimination ..................................................................................................... 38
3.2.5. Pharmacokinetic interactions with other medicinal products .................................. 38
3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal
preparation(s) and constituents thereof ....................................................................... 39
3.3.1. Single dose toxicity .......................................................................................... 39
3.3.2. Repeated dose toxicity ..................................................................................... 40
3.3.3. Genotoxicity ................................................................................................... 40
3.3.4. Carcinogenicity................................................................................................ 40
3.3.5. Reproductive and developmental toxicity ............................................................ 42
3.3.6. Local tolerance ................................................................................................ 45
3.3.7. Other special studies ........................................................................................ 45
3.4. Overall conclusions on non-clinical data ................................................................ 46
4. Clinical Data ..................................................................................................................... 48
Page 2/120
5.1. Overview of toxicological/safety data from clinical trials in humans ......................... 111
5.2. Patient exposure .............................................................................................. 111
5.3. Adverse events and serious adverse events and deaths ........................................ 111
5.4. Laboratory findings ........................................................................................... 118
5.5. Safety in special populations and situations ......................................................... 118
5.6. Overall conclusions on clinical safety ................................................................... 118
6. Overall conclusions ........................................................................................................ 119
Annex ................................................................................................................................ 120
Page 3/120
1. Introduction
1.1. Description of the herbal substance(s), herbal preparation(s) or
combinations thereof
Herbal substance(s)
There is a monograph on Ginkgo leaf published in the European Pharmacopoeia (Ph. Eur. 7th edition
2012 (7.5), ref. 01/2011:1828).
The herbal substance consists of the whole or fragmented, dried leaf of Ginkgo biloba L.
The leaf is greyish or yellowish-green or yellowish-brown. The upper surface is slightly darker than the
lower surface. The petioles are about 4-9 cm long. The lamina is about 4-10 cm wide, fan-shaped,
usually bilobate or sometimes undivided. Both surfaces are smooth, and the venation dichotomous, the
veins appearing to radiate from the base; they are equally prominent on both surfaces. The distal
margin is incised, irregularly and to different degrees, and irregularly lobate or emarginate. The lateral
margins are entire and taper towards the base.
Synonyms: Fossil tree, Kew tree, Maidenhair Tree, Yin Xing (whole plant), Yin Xing Ye (leaves)
Constituents: (Chan 2007, van Beek 2000)
Terpenes
-
Carotenoids
Volatile terpenes
Flavanols (catechins)
Organic acids
Polyacetate derived compounds
-
Alkyl phenolic acids and alkyl phenols (ginkgolic acid, cardanols (approx. 0.1%))
Lipids
Herbal preparation(s)
1. Ginkgo biloba dry extract is a component part of the European Pharmacopoeia. Actually the
following monograph exists:
Page 4/120
Ginkgo dry extract, refined and quantified (Ph. Eur. 7th edition 2012 (7.5), ref.
04/2008:1827)
This extract contains several chemical constituents, among which the two main constituents
flavones glycosides (total 22.0-27.0%), represented by quercetin, kaempherol and
isorhamnetin and terpene lactones (total 5.0-7.0), represented by ginkgolides A, B, C (2.83.4%) and bilobalide (2.6-3.2%). The content of ginkgolic acids is limited with max. 5 ppm.
The limit value of 5 ppm was chosen since it complies with the detection limit recordable by
routine methods, thus allowing to assure to a maximum degree removal of these compounds
from therapeutically used extracts.
2. Powdered herbal substance
Since when on
pharmaceutical form
Posology/daily dosage
film-coated tablets
containing 80 mg extract
the market?
1. 2000
Page 5/120
2. 1993
3. 1993
film-coated tablets
containing 40 mg extract
drops
1 ml solution contains 40 mg
extract
4. 1999
film-coated tablets
5. 1999
6. 1999
oral solution
1.33 g extract
weeks
film-coated tablets
containing 40 mg extract
initial treatment:
3 times daily 1 tablet for 8-12 weeks
follow-up treatment:
if required 2 times daily 1 tablet
dementia syndrome: 3 times daily 1-2 tablets
7. 1999
drops
1 mg (appropriate to 18
40 mg extract
8. 1989
film-coated tablets
containing 40 mg extract
follow-up treatment:
if required 2 times daily 1 tablet
dementia syndrome: 3 times daily 1-2 tablets
9. 1989
drops
1 ml contains 40 mg extract
10. 1993
coated tablets
containing 20 mg extract
Indications:
1. For the symptomatic treatment of brain-related impairment of mental performance, memory
impairment, impaired concentration, depressive mood, dizziness, and headache
2. Decrease of the brain performance with lack of concentration and weakness of memory, cold
hands and feet with numbness, prickle, and calf pain at walking
3. Frequently occurring vertigo and tinnitus (clarification by a doctor), hearing loss (clarification
by a doctor)
4. Decrease of the brain performance (such as weakness of memory, anxiety, depressive mood,
cold hands and feet
5. See 4.
6. Cerebral insufficient blood supply or rather brain disorder with symptoms of decreasing
intellectual performance and vigilance such as dizziness, tinnitus, headache, sight disorder,
weakness of memory, anxiety and depressive mood, dementia syndrome. Peripheral arterial
circulatory disorders with preservative perfusion reserve (claudication intermittent). For
supportive treatment of impaired hearing because of a cervical syndrome.
7. See 6.
Page 6/120
8. Cerebral insufficient blood supply and malnutrition or rather brain disorders with the symptoms
of decreasing intellectual performance and vigilance such as dizziness, headache, sight
disorder, weakness of memory, anxiety and depressive mood.
9. See 8.
10. See 8.
pharmaceutical form
Posology/daily dosage
capsules, hard
containing 60 mg extract
2.
film-coated tablets
a) 2000
a) containing 40 mg extract
b) 2006 (line
b) containing 120 mg
extension)
extract
the market?
1. 1998
a) coated tablets
containing 40 mg extract
b) 2002
b) oral solution
Indications:
1. Symptomatic treatment of disturbance in the cerebral functions, after exclusion of all serious
pathologies; (OTC)
2. To delay the pathological symptoms typical of mild to moderate Alzheimer-type dementia with
its concomitant disturbances in memory and problems in concentrating. The primary target
group includes patients with dementia syndrome as a consequence of degenerative dementia,
vascular dementia and mixed (hybrid) forms. Before initiating the therapy, it should be
excluded that the disorder is caused by a specific underlying disease that needs other specific
treatment. (medical prescription)
3. To delay the pathological symptoms typical of mild to moderate Alzheimer-type dementia with
its concomitant disturbances in memory and problems in concentrating. The primary target
group includes patients with dementia syndrome as a consequence of degenerative dementia,
vascular dementia and mixed (hybrid) forms. Before initiating the therapy, it should be
Page 7/120
excluded that the disorder is caused by a specific underlying disease that needs other specific
treatment. (medical prescription).
Used in case of subjective symptoms of venous insufficiency of the lower limbs, such as heavy
legs, after exclusion of all serious pathologies (such as flebitis, thromboflebitis, thrombosis).
Czech Republic: Well-established use
1. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (m/m);
(EGb 761) for specification see additional comments
2. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (m/m);
(EGb 761) for specification see additional comments
3. See 1.
4. See 2.
5. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (V/V); for
specification see additional comments
6. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (V/V); for
specification see additional comments
7. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (V/V); for
specification see additional comments
8. Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (V/V); for
specification see additional comments
Since when on
pharmaceutical
the market?
form
1. 1992
1 ml contains 40 mg
extract
Posology/daily dosage
2. 1992
film-coated tablets
containing 40 mg
extract
3. 1995
1 ml contains 40 mg
extract
4. 1995
film-coated tablets
containing 40 mg
extract
Page 8/120
1 ml contains 40 mg
extract
6. 2002
film-coated tablets
contains 40 mg
extract
7. 2006
film-coated tablets
containing 80 mg
extract
8. 2006
film-coated tablets
containing 120 mg
extract
For all products: In dizziness and tinnitus of vascular or involution character treatment longer than 6-8
weeks does not have any therapeutically benefit
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 9/120
Indications:
1. Syndrome of dementia (primary degenerative dementia of Alzheimer type, vascular dementia,
mixed forms of dementia); for treatment of symptoms such as (loss of concentration; memory
disturbances, emotional lability) in elderly, based on chronic cerebrovascular insufficiency;
peripheral blood circulation and microcirculation disorders: peripheral arterial obstructive
disease of hind limbs at stadium 1-II according to Fontaine (claudicatio intermittens), Raynaud
syndrome, acroparesthaesia, enhanced capillary fragility, etc.; sensory disorders based on
vascular insufficiency (vertigo, tinnitus, hearing impairment and vision impairment in elderly
based on insufficient blood circulation in retina
2. See 2.
3. Syndrome of dementia (primary degenerative dementia of Alzheimer type, vascular dementia,
mixed forms of dementia); brain function disorders such as memory and concentration
disturbances, depression, dizziness, tinnitus, head aches due to organic dysfunction of CNS as
a part of complex dementia therapy; peripheral obliterating arteriopathy at stadium II
according to Fontaine scale; dizziness and tinnitus of vascular or involution character
4. See 3.
5. For symptomatic treatment of cerebral insufficiency such as memory and concentration
disturbances, emotional lability, dizziness, tinnitus and head aches; mild to moderate dementia
syndromes including primary degenerative dementia, vascular dementia and mixed forms;
peripheral arterial occlusive disease (claudicatio intermittens); dizziness and tinnitus of
vascular or involution character
6. See 5.
7. See 5.
8. See 5.
Risks:
1. Contraindications: hypersensitivity to the drug substance, bleeding dispositions. Special
warning: Not to be used in pregnancy and lactation, and in children bellow 12 years, not
intended for hypertension therapy. Interactions: caution is recommended in concomitant use
with salicylates and barbiturates. Undesirable effects: in isolated cases gastrointestinal
discomfort such as nausea, diarrhoea, very rare palpitation, hypotension, arrhythmia,
retrosternal pain
2. See 1.
3. Contraindications: hypersensitivity to the drug substance, bleeding dispositions. Special
warning: Not to be used in pregnancy and lactation, and in children bellow 12 years, not
intended for hypertension therapy. Caution is recommended in case of concomitant use of
medicinal products with similar effect (vasodilatants, medicinal products causing tachycardia
etc.). Undesirable effects: in isolated cases gastrointestinal discomfort, headaches, congestion,
allergic skin reactions, very rare haemorrhage
4. See 3.
5. Contraindications: hypersensitivity to the drug substance. Special warning: Not to be used in
children bellow 12 years, not recommended in haemorrhage, caution is recommended in case
of concomitant use of medicinal products with similar effect (vasodilatants, antiarrythmics).
Page 10/120
Release specification
Stability specification
22.026.4 g/100 g
22.026.4 g/100 g
(DAB+Ph.Eur. 22.027.0 %)
5.46.6 g/100 g
5.46.6 g/100 g
(DAB 5.07.0 %)
Assays
-Ginkgoflavonglycosides (HPLC)
- Terpene lactones (HPLC)
Ginkgolides A,B,C
2.83.4 g/100 g
2.63.2 g/100 g
Proanthocyanidins (photometry)
NMT 9.5 %
Biflavones (HPLC)
NMT 0.1 %
Bilobalide
Preparations 5) 8)
Ginkgo biloba dry extract standardised to 35-67:1; extraction solvent acetone 60% (V/V); specification
Test
Limit
Assays
- GinkgoflavonglycosidesHPLC
NLT 24.029.0 %
- TerpenesGC
Ginkgolides A,B,C,J and bilobalide
- Ginkgolides A, B and C
NLT 6.09.0 %
2.63.2 %
During second half of the year (2008) specification will be adapted in accordance with the Ph.Eur.
monograph 04/2008:1827
Page 11/120
pharmaceutical form
Posology/daily dosage
film-coated tablets
MA in 1995
containing 40 mg extract
market?
to lack of experience
2. marketed around 1990,
film-coated tablets
MA in 1996
3. 2005
film-coated tablets
film-coated tablets
not indicated
film-coated tablets
containing 40 mg extract
Indications:
1.
2. See 1.
3. Not indicated
4. Not indicated
5.
See 1.
Risks:
1. Products with ginkgo leaf should not be used in the weeks up to a planned surgery; patients that
experience spontaneous bleeding during treatment with ginkgo leaf should stop the treatment
and contact a doctor; caution in epileptics, ginkgo leaf may decrease the effect of antiepileptic
drugs or increase the vulnerability of seizures
The following text is from the SPC in DK:
Interactions with other medicinal products and other interactions:
Page 12/120
Antiepileptika: As stated in the chapter contraindiations in the SPC of DK: Sensitivity for ginkgo
leaves or one of the auxiliary agents
Orale antikoagulantia: Might increase the effect of oral anticoagulant
NSAID: Possible increased risk of bleedings in NSAID including acetylsalicylic acid.
Calcium antagonists: Concomitant intake of ginkgo leaf and nifedipine has caused an increased heart
frequency of 5-10% in well beings. The mechanism is not clear. Ginkgo leaf does not affect the
pharmacokinetic of nifedipine in concomitant intake in well volunteers. The combination can be used.
Proton pump inhibitors: Ginkgo leaf (multiple doses) decrease AUC for a single dose omeprazole with
25-40% and increase clearance for omeprazole from 30-45% due to an induction of omeprazoles
metabolism in CYP2C19. The interaction is not seen as clinical important. The combination can be
used.
Anti-diabetics, sulfonamides: Ginkgo leaf (multiple doses) decreases AUC for a single dose tolbutamide
with around 15%. The mechanism is not clear. The combination can be used.
The effect of concomitant intake of other medicinal products included medicine bought in other
countries and other herbal medicinal products is not known.
Side effects:
1. seldom: increased tendency to bleeding*, headache, nausea, gastrointestinal disturbances
very seldom: dizziness (vertigo), allergic skin reactions like rash and itching
*Bleeding has been noted in a single case after long-term treatment with ginkgo leaves. Clinical
sudies with standardised extracts have not shown any effect on coagulation.
2.
See 1.
Additional comments:
We have for the time being 15 products with extract of GB with a MA. The rest are similar to the above
mentioned products, since several companies have identical versions of their products, sold with other
names. But the listed are the different extract forms as far I can see. We also have had other products
with a MA or applied for an MA, but they are either withdrawn or did not receive an MA.
Page 13/120
6. Dry extract from ginkgo leaf, corresponding to 26.4-32.4 mg of flavones glycosides and 6.08.4 mg terpene lactones (ginkgolides, bilobalide); extraction solvent: acetone 60% (V/V); 1
tablet contains less than 0.6 g ginkgolic acids; DER 35-67:1
Since when on
pharmaceutical form
Posology/daily dosage
tablets
the market?
1. 1998
containing 40 mg extract
oral solution
1 ml contains 40 g extract
2. 1999
film-coated tablets
containing 60 mg extract
3. 2000
film-coated tablets
coated tablets
containing 80 mg extract
6. 2004
coated tablets
France:
One product (ginkgo powder 180 mg) has been on the market as food supplement.
Since when on
pharmaceutical form
Posology/daily dosage
Hard capsule
the market?
1984
Page 14/120
Page 15/120
18-36 drops (1-2 ml) 3 times daily (=120-240 mg): No. 10, 55-58, 64, 66, 68, 70, 109
2-4 pumps (1-2 ml) 3 times daily (=120-240 mg): No. 14
20-40 drops (1-2 ml) 2-3 times daily (=80-240 mg): No. 15
1 tablet 3 times daily or 2 tablets 2 times daily (=120-200 mg): No. 21-22, 24
1 tablet 2-3 times daily (=160-240 mg): No. 42-45, 59-62, 77, 80, 82-84, 88, 101-102, 107, 110
1 tablet 2 times daily (=120-240 mg): No. 51-54, 79, 81, 112-114
1 tablet 1-2 times daily (=120-240 mg): No. 73-76, 85-87, 89
0.5-1 tablet 2 times daily (=120-240 mg): No. 78, 90-91, 94-98, 111
0.5 tablet 2 times daily (=240 mg): No. 104-106, 115-117
For the symptomatic treatment of brain-related impairment of mental performance
1-2 tablets 3 times daily (=120-240 mg): No. 11
17-34 drops (1-2 ml) 3 times daily (=120-240 mg): No. 12
1-2 capsules 3 times daily (=120-240 mg): No. 13, 18-19
25-50 drops (1-2 ml) 3 times daily (=120-240 mg): No. 16-17, 20
Peripheral arterial occlusive disease, vertigo, as an adjuvant in tinnitus
1.5-2 tablets 2 times daily (=120-160 mg): No. 9, 46-50, 63, 65, 67, 69, 103, 108
25 drops (1,25 ml) 3 times daily or rather 40 drops (2 ml) 2 times daily (=150-160 mg): No. 6
20-25 drops (1-1.25 ml) 3 times daily or rather 30-40 drops (1.5-2 ml) 2 times daily (=120-160 mg):
No. 5, 7, 40
20 drops (1 ml) 3 times daily or rather 40 drops (2 ml) 2 times daily (=120-160 mg): No. 8, 23, 2930, 39, 41
27-36 drops (1.5-2 ml) 2 times daily (=120-160 mg): No. 10, 55-58, 64, 66, 68, 70, 109
2 pumps (1 ml) 3 times daily or rather 4 pumps (2 ml) 2 times daily (=120-160 mg): No. 14
20 drops (1 ml) 3 times daily or rather 40 drops (2 ml) 2 times daily (=120-160 mg): No. 15
1 tablet 3 times daily or 2 tablets 2 times daily (=120-200 mg): No. 31-38, 71-72, 99-100
1 tablet 3 times daily (=150 mg): No. 21-22, 24
1 tablet 2 times daily (=120-240 mg): No. 42-45, 59-62, 77, 80, 82-84, 88, 101-102, 110
1 tablet 1-2 times daily (=120-240 mg): No. 51, 53-54, 79, 111-114
1 tablet 1 time daily (=120 mg): No. 73-76, 85-87, 89
For increasing the pain-free walking distance in patients with arterial occlusive disease, vertigo and
tinnitus of vascular and involutive origin
1.5-2 tablets 2 times daily (=120-160 mg): No. 11
26-34 drops (1.5-2 ml) 2 times daily (=120-160 mg): No. 12
Page 16/120
For increasing the pain-free walking distance in patients with arterial occlusive disease, vertigo and
tinnitus
1 capsule 3 times daily or rather 2 capsules 2 times daily (=120-160 mg): No. 13, 18, 19
25 drops (1 ml) 3 times daily or rather 50 drops (2 ml) 2 times daily (=120-160 mg): No. 16-17, 20
1 tablet 3 times daily or 2 tablets 2 times daily (=120-200 mg): No. 25
Route of administration:
For taking the medicinal product 3 times daily it should be consumed in the morning, in the afternoon
and in the evening, for a daily use of 2 times it should be taken in the morning and in the afternoon.
For film-coated tablets and hard capsules
Do not take the film-coated tablets or the hard capsules in a supine position. The tablet/capsule is
swallowed whole (not chewed) with some liquid, preferably a glass of drinking water. It can be taken
with or without a meal.
For oral drops and oral liquids
The drops are taken undiluted or in some water and afterwards washed down sufficient liquid,
preferably a glass of drinking water. The drops can be taken with or without a meal.
For effervescent tablet
The effervescent tablets are dissolved by stirring in a glass of drinking water, about 200 ml. The
tablets can be taken with or without a meal.
Duration of use:
Dementia syndrome
Treatment should last for at least 8 weeks. If there is no symptomatic improvement after 3 months, or
if pathological symptoms should intensify, the doctor should check whether continuation of treatment
is still justified.
Peripheral arterial occlusive disease
A treatment period of at least 6 weeks is required for improving performance with regard to walking
distance.
Vertigo
No therapeutic benefit is gained by extending use beyond a 6 to 8-week period.
Tinnitus
Adjuvant therapy should be administered over a period of at least 12 weeks. If treatment is
unsuccessful after 6 months, success can no longer be expected even after prolonged treatment.
Indications:
a) For the symptomatic treatment of brain-related impairment of mental performance, as part of an
overall therapeutic strategy in dementia syndromes with the following main symptoms: memory
impairment, impaired concentration, depressive mood, dizziness, tinnitus, headache.
b) For increasing the pain-free walking distance in patients with arterial occlusive disease of the legs
(Fontaine Stage II intermittent claudication), as part of physiotherapy, including gait training.
Page 17/120
c)
a-d: No. 1, 4, 8, 29-32, 35-36, 38, 45-46, 48, 51, 53-54, 65, 67, 72, 93, 103, 108-114
a, b, e: No. 2, 5, 7, 9-14, 16-21, 25, 33-34, 37, 39-44, 47, 49-50, 55-64, 66, 68-71, 77, 82-89
a: No. 3, 52, 73-76, 78-79, 81, 90-91, 94-98, 104-107, 115-117
a, b: No. 6
a-c, f: No. 15, 22-24, 26-28, 80, 92, 99-102
Risks:
Contraindications:
Hypersensitivity to Ginkgo biloba extracts or to any other component of the medicinal product.
Pregnancy.
Special warnings and precautions for use:
There are no adequate studies on the use of medicinal products containing Ginkgo biloba in children
and adolescents. It must therefore not be used in children below 12 years: No. 11-13, 15-18, 20-28,
46, 48, 78, 90-91, 94-97, 99-102, 108-110. All other products must be used in adults aged 18 or over.
In abnormal increased tendency to bleed (haemorrhagic diathesis) and concomitantly treatment with
anticoagulants the medicinal product only should be taken after consulting a doctor.
As there is evidence to suggest that preparations containing Ginkgo biloba might increase susceptibility
to bleeding, these medicinal products must be discontinued as a precaution prior to surgery.
In patients with epilepsy, onset of further seizures - promoted by intake of ginkgo preparations cannot be excluded. It has been argued that this might be associated with the 4-O-methylpyridoxine
content.
Interactions:
If a preparation containing Ginkgo biloba is taken concomitantly with anticoagulants (e.g.
phenprocoumon, warfarin, clopidogrel, acetylsalicylic acid and other non-steroidal anti-inflammatory
drugs), their effect may be potentiated.
As with any medicinal product, it cannot be ruled out that any preparation containing Ginkgo biloba
may influence the metabolism via cytochrome P450 3A4, 1A2 and 2C19 of various other medications,
which could affect the potency and/or duration of action of the medications concerned. No adequate
studies are available on this matter.
Pregnancy and lactation:
There is isolated evidence which suggest that preparations containing Ginkgo biloba can increase
susceptibility to bleeding. Therefore preparations containing Ginkgo biloba must not be used during
pregnancy (see section Contraindications).
Page 18/120
There are no adequate studies on the use of medicinal products containing Ginkgo biloba during
lactation. Therefore preparations containing Ginkgo biloba must not be used during lactation. It is not
known whether the ingredients of the extract pass into breast milk.
Undesirable effects:
It is not possible to give any definite data on the frequency of undesirable effects reported with the
intake of preparations containing Ginkgo biloba, as such undesirable effects have emerged via
individual reports by patients, doctors or pharmacists. According to these reports, the following
undesirable effects might occur in patients taking this medicine:
Bleeding of individual organs may occur, particularly with concomitant intake of anticoagulants, e.g.
phenprocoumon, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (see also section
Interactions).
Allergic shock may occur in hypersensitive individuals; allergic skin reactions (erythema, swelling of
the skin, itching) may also occur.
Mild gastrointestinal complaints
Headache, dizziness or aggravation of pre-existing symptoms of dizziness may occur.
The herbal substance is not on the market.
pharmaceutical form
Posology/daily dosage
Capsule, hard
1-2 tablets
Film-coated tablet
1-2 tablets
Since when on
pharmaceutical form
Posology/daily dosage
Capsule, hard
the market?
1993
Page 19/120
pharmaceutical form
Posology/daily dosage
Before 1980
Capsule, hard
Indications:
In mild disorders of peripheral circulation with feeling of cold hands and legs; adjunctively in mild agelinked impairment of intellectual capability
Risks:
Adverse drug reaction:
Gastrointestinal complaints (nausea, constipation, diarrhoea), headache, sleep disorders, palpitation,
vertigo anxiety, hypersensitivity reactions (pruritus, erythema), bleeding
Page 20/120
Interactions:
Concomitant use with anticoagulants, antiplatelet medicines, tipranavir, herbal drugs containing Allium
sativum or Panax ginseng increases risks of bleeding; use with caution in patients simultaneously
treated with inhibitors of proton pump (decreased efficacy of IIPs), trazodone (risk of increased
adverse drug reaction of nifedipine), thiazides (risk of increased blood pressure)
Warnings:
Patients with coagulation disorders should not use this drug without medical supervision; the treatment
must be stopped 36 hours before surgical or dental operation
The herbal substance is on the market.
Additional comments:
Other herbal medicinal products than well-established use and traditional herbal medicinal products:
1. Ginkgo biloba leaf dry extract (35-67:1) containing 24-29% of flavone glycosides, 6-9% of
trepene lactones, 2.6-3.2% of bilobalide; extraction solvent: Acetone 60% (V/V)
2. Ginkgo biloba leaf dry extract (35-67:1) containing 22-26.4% flavone glycosides, 2.8-3.4% of
ginkgolides A, B and C, 2.6-3.2% of bilobalide; extraction solvent: Acetone 60% (m/m)
3. Ginkgo biloba leaf dry extract (35-67:1) corresponding to 8.8-10.8 mg of flavone glycosides,
1.12-1.3 mg of ginkgolides, 1.04-1.28 mg of bilobalide; extraction solvent: Aceton 60% (m/m)
4. Ginkgo biloba leaf dry extract containing 21.6-26.4% of flavone glycosides, 2.8-3.4% of
ginkgolides A, B and C, 2.6-3.2% of bilobalide; extraction solvent: Acetone 60% (m/m)
5. Ginkgo biloba leaf dry extract (35-67:1) containing 22-27% of ginkgoflavonglycosides, 5-7% of
terpene lactones including 2.8-3.4% of ginkgolides A, B, C and 2.6-3.2% of bilobalide;
extraction solvent: Acetone 60% (m/m)
6. Ginkgo biloba leaf dry extract (40-50:1) containing 24-27% flavone glycosides, 2.8-3.4% of
ginkgolides A, B and C, 2.6-3.2% of bilobalide; extraction solvent: Acetone 60 % (V/V)
7. Ginkgo biloba leaf dry extract (35-67:1) corresponding to 19.2-23.2 mg of flavone glycosides
and 4.8-7.2 mg of terpene lactones (ginkgolides, bilobalide); extraction solvent: Acetone 60%
(V/V)
8. Ginkgo biloba leaf dry extract (45-55:1) containing not less than 6 mg of
ginkgoflavoneglycosides and 2-2.8 mg terpene lactones; extraction solvent: Ethanol 70% (V/V)
9. Ginkgo biloba leaf tincture (1:5); extraction solvent: Ethanol 60% (V/V)
10. Ginkgo biloba leaf tincture (1:5); extraction solvent: Ethanol 70% (V/V)
Since when on
Pharmaceutical form
Posology/daily dosage
Capsule, hard
containing 40 mg extract
the market?
1. 1993
Film-coated tablet
Containing 40 mg extract
daily
Film-coated tablet
containing 40 mg extract
Page 21/120
Since when on
Pharmaceutical form
Posology/daily dosage
the market?
improvement are observed after 4-week treatment,
use of 1 tablet 2 times daily as a maintenance
treatment is recommended
4. 1999
Film-coated tablet
containing 40 mg extract
5. 2001
Film-coated tablet
containing 80 mg extract
6. 2002
7. 2004
Film-coated tablet
containing 40 mg extract
Capsule, hard
containing 80 mg extract
8. 2004
Film-coated tablet
containing 40 mg extract
use: up to 10 weeks
9. 1997
Oral liquid
10. 1992
Oral liquid
Indications:
1. In cerebral circulation disorders with such symptoms as: impairment of memory and
intellectual capability, vertigo and tinnitus. Adjunctively in disorders of peripheral circulation
with pain during walking or feeling of cold hands and legs.
2. As symptomatic treatment in first signs of cognitive disorders caused by impaired cerebral
circulation (memory and concentration disorders); in microcirculation disorders (vertigo and
tinnitus); adjunctively for treatment of symptoms of peripheral circulation disorders
(contractions, feeling of cold legs)
3. (a) In cerebral circulation disorders with such symptoms as weakened concentration, memory
impairment, headache and vertigo, tinnitus, impaired sight and hearing
(b) In disorders of peripheral circulation with accompanying feeling of cold legs or pain
4. (a) In elderly patients manifesting impaired cognitive and neurosensorial functions (except for
Alzheimers disease and other states of profound dementia). In cerebral circulation disorders
with such symptoms as vertigo and tinnitus, impaired sight and hearing
(b) Adjunctively for treatment of symptoms of peripheral circulation disorders intermittent
claudication in chronic peripheral obliterative arterial disease (stage 2)
(c) Adjunctively for treatment of Raynauds disease symptoms
5. See 3.
6. In cerebral circulation disorders with such symptoms as: impairment of memory and
intellectual capability, headache and vertigo, tinnitus. Adjunctively in disorders of peripheral
circulation (intermittent claudication, pains in legs, acanthaesthesia)
7. (a) In age-linked impairment of memory and intellectual capability
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 22/120
(b) Adjunctively in cerebral circulation disorders with manifestations like vertigo and tinnitus
(c) Adjunctively in disorders of peripheral circulation with pain during walking or feeling of cold
hands and legs
8. Adjunctively in cerebral circulation disorders with such symptoms as vertigo and tinnitus;
adjunctively in disorders of peripheral circulation (feeling of cold hands and legs, dysaesthesia,
acanthaesthesia)
9. In disorders of peripheral circulation ; adjunctively in cerebral circulation disorders
10. In peripheral circulation disorders
Risks (adverse drug effects, lliteratrue):
Adverse drug reactions:
1. Very rarely gastrointestinal complaints (nausea, constipation, diarrhoea), headache,
hypersensitivity reactions (pruritus, erythema)
2. Bleeding, mild gastrointestinal complaints, headache, vertigo, allergic skin lesions
3. See 1.
4. Gastrointestinal complaints, headache, skin lesions
5. See 1.
6. Very rarely skin lesions (pruritus, erythema), gastrointestinal complaints, headache
7. See 1.
8. See 6.
9. See 4.
10. See 4.
Interactions:
1. Concomitant use with acetylsalicylic acid or antithrombotic medicines increases the risks of
haemorrhage
2. The medicinal product may enhance action of antithrombotic medicines
3. Concomitant use with acetylisalicylic acid, warfarin or thiazides is not recommended
4. Not indicated
5. See 3.
6. Concomitant use with warfarin is not recommended, in case of simultaneous use with
acetylsalicylic acid control of patient state is advised
7. See 1.
8. Possible interactions with anticoagulants, antiplatelet medicines, MAO inhibitors, thiazides,
trazodone, fluoxetine, buspirone, herbal drugs containing Hypericum perforatum, melatonin,
insulin, drugs metabolised by cytochrome P450 3A4
9. Possible interactions with antithrombotic medicines
10. Not indicated
Contraindications:
1.-8. + 9.-10.: Hypersensitivity to components of the medicinal product
Warnings:
1. Not indicated
2. The treatment should be stopped before planned surgery; patients with coagulation disorders
or using antithrombotic medicines should not use this medicinal product without medical
supervision; increase in frequency of epileptic seizures cannot be excluded
3. Not indicated
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 23/120
4. Not indicated
5. Not indicated
6. The product is not recommended in case of patients showing predispositions to bleedings
7. See 6.
8. The product may cause prolongation of coagulation time
9. Linked to ethanol content
10. See 12.
Combination products:
Combination products with Ginkgo biloba and Allium sativum, Panax ginseng, diverse vitamins,
Aesculus hippocastanum, Crataegus monogyna and/or Crataegus laevigata, Viscum album, Arnica
Montana and Cynara scolymus exist in Poland.
pharmaceutical form
Posology/daily dosage
1989
tablets 40 mg
1 ml 3 times daily
Indications:
Peripheral vascular disturbances arteriopathy of the legs and its trophic complications; distal
microcirculation disturbances (Raynaud). Brain vascular disturbances memory, affectivity, behaviour,
vertigo, headaches, and brain circulatory insufficiency; stroke sequels, migraine. Neurosensory and
otovestibular disturbances like hearing loss, tinnitus and vertigo.
There were pharmacovigilance actions taken on the medicinal product containing the herbal substance.
pharmaceutical form
Posology/daily dosage
capsule, containing 40 mg
standardised extract
oral solution, containing 40 mg/ml
standardised extract
Indications:
Symptoms associated with cerebral insufficiency, such as memory lost and depression; pathologic
cognitive deficiency in the elderly; peripheral arterial occlusive disease in Stage II (intermittent
claudication, Raynauds syndrome, acrocyanosis); neurosensory disorders of vascular origin (vertigo,
tinnitus, acuphenes)
Page 24/120
Risks:
Patients with known hypersensitivity to Ginkgo biloba preparations or to any of the excipients
The herbal substance is not on the market.
Additional comments:
Ginkgo biloba dry extract comply with Ph. Eur. monograph 1827/2008
Spain: Well-established
1.
Tanakene
2.
3.
4.
pharmaceutical form
Posology/daily dosage
1. 1977
2. 1996
film-coated tablets 70 mg
3. 1994
film-coated tablets 40 mg
4. 2003
film-coated tablets 40 mg
Indications:
For all products: Symptomatic treatment of cerebrovascular and peripheral vascular disorders
pharmaceutical form
Posology/daily dosage
1. 1990
capsules 180 mg
2. 1992
tablets 460 mg
3. 1998
capsules 400 mg
Indications:
For all products: Vertigo, heavy legs, haemorrhoids
Page 25/120
pharmaceutical form
Posology/daily dosage
film-coated tablets
market?
1. 2003, reclassified
to THMP 2012
2. 1998, reclassified
to THMP 2012
3. 1997, reclassified
to THMP 2012
4. 1997, reclassified
oral solution
to THMP 2012
5. 1997, reclassified
film-coated tablets
to THMP 2012
Indications:
For all products: Traditional herbal medicinal product for the treatment of long-standing symptoms in
elderly people such as difficulties of memory and concentration, vertigo, tinnitus and fatigue. Prior to
use other serious conditions should have been ruled out by a physician.
The indications are based solely on experience and use during a long period of time.
Risks:
Contraindications:
Hypersensitivity to the active substance
Special warnings and precautions for use:
The use in children and adolescents under 18 years of age is not recommended because of concerns
requiring medical advice.
If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be
consulted.
In patients with a pathologically increased bleeding tendency (haemorrhagic diathesis) and
concomitant anticoagulant treatment, the medicinal product should only be used after consultation
with a doctor.
Preparations containing ginkgo might increase susceptibility to bleeding, the medicinal product should
be discontinued as a precaution two weeks prior to surgery.
In patients with epilepsy, onset of further seizures promoted by intake of ginkgo preparations
cannot be excluded. It has been argued that this might be associated with the 4-O-methylpyridoxine
content.
Interactions:
The interaction potential of Ginkgo biloba has been investigated in several clinical studies. However,
[name of product] may not have been studied specifically and it is possible that [name of product] may
have a weaker or more pronounced interaction potential.
Ginkgo biloba containing products have in some studies been observed to give a modest induction of
drug metabolising enzymes, such as CYP3A4, CYP2C9 and CYP2C19. It cannot be excluded that other
co-regulated enzymes, such as UGTs (catalysing glucuronidation) may be induced as well. As induction
gives rise to increased synthesis of enzymes, the net result is mild to moderate decreases in the
plasma concentrations of the drugs metabolised by these enzymes. Induction is generally very variable
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 26/120
between individuals. The available study results are somewhat contradictory and it has also been
observed that CYP3A4 may be mildly inhibited, resulting in a reduced enzyme activity and increased
drug levels. As the observed inducing and inhibitory effects are quite small, this is likely not to be of
clinical relevance for most drugs, but it may, however, be relevant for drugs with a narrow therapeutic
index and in some patients.
Available studies with warfarin do not indicate that there is an interaction between warfarin and Ginkgo
biloba products, but adequate monitoring is advised when starting, when changing Ginkgo biloba dose,
when ending Ginkgo biloba intake or if changing product.
An interaction study with talinolol indicates that Ginkgo biloba may inhibit P-glycoprotein at the
intestinal level. This may give rise to increased exposure of drugs markedly affected by P-glycoprotein
in the intestine such as dabigatran etexilate. Caution is advised if combining G. biloba and dabigatran.
One interaction study has indicated that the C max of nifedipine may be increased by G. biloba. In some
individuals, increases by up to 100% were observed resulting in dizziness and increased severity of hot
flushes.
In theory, it cannot be excluded that the effectiveness of oral contraceptives may be slightly reduced in
certain individuals, why it is important to have a good compliance to the contraceptive dosing regimen.
Fertility, pregnancy and lactation:
The use should be avoided during pregnancy and lactation as there is isolated evidence to suggest that
preparations containing ginkgo can increase susceptibility to bleeding.
Undesirable effects:
Increased risk of bleeding*, palpitations, arrhythmia, restlessness, insomnia, headache, dizziness,
gastrointestinal complaints, exanthema, itching, and urticaria.
The frequencies of the adverse effects are not known.
*After longtime treatment with products containing Ginkgo biloba extracts, a few cases of bleeding
have been reported (no more details on the extracts given in the reports). However, in clinical studies
with standardised extracts, no effect on coagulation has been reported.
If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.
The herbal substance is on the market.
There were pharmacovigilance actions taken on the medicinal product containing the herbal substance.
Additional comments:
The following products have been registered according to a previous national registration scheme (so
called registered naturmedel):
Brandname 80 mg (30:1) 2x2, reg Naturmedel 1986
Brandname 40 mg (EGb 761) 1x2-3, reg Naturmedel 1988
Brandname 250 mg 1x3, reg Naturmedel 1989
Page 27/120
pharmaceutical form
Posology/daily dosage
hard capsule
containing 40 or 80 mg extract
market?
1998
Indications:
Treatment of symptoms of mild to moderate cerebral insufficiency and peripheral arterial occlusive
disease
Risks:
Adverse effects: gastrointestinal problems, headache and hypersensitive reactions
There were no pharmacovigilance actions taken on the medicinal product containing the herbal
substance.
Since when on
pharmaceutical form
Posology/daily dosage
capsule, hard
40 mg 3 times daily
the market?
1. 1996
film-coated tablet
3. 1992
40 mg 3 times daily
Page 28/120
length, that patient (state II of claudicatio intermittens according to Fontaine) is able to walk
over without pain.
3. Dementia syndromes. Claudicatio intermittens, Raynaud syndrome, increased capillary
fragility. Sensory disorders based on venous insufficiency hypacusis, vertigo, tinnitus.
Risks:
1. Gastrointestinal disorders, headache, allergic reactions on skin.
2. Gastrointestinal disorders, headache, allergic reactions on skin. Haemorrhage in combination
with NSAID.
3. Gastrointestinal disorders, headache, allergic reactions on skin. Palpitations, hypotension,
arrhythmias.
There were no pharmacovigilance actions taken on the medicinal product containing the herbal
substance.
Regulatory Status
Comments
Austria
MA
TRAD
Other TRAD
Other Specify:
Belgium
MA
TRAD
Other TRAD
Other Specify:
Bulgaria
MA
TRAD
Other TRAD
Other Specify:
Croatia
MA
TRAD
Other TRAD
Other Specify:
Cyprus
MA
TRAD
Other TRAD
Other Specify:
Czech Republic
MA
TRAD
Other TRAD
Other Specify:
Denmark
MA
TRAD
Other TRAD
Other Specify:
Estonia
MA
TRAD
Other TRAD
Other Specify:
Finland
MA
TRAD
Other TRAD
Other Specify:
France
MA
TRAD
Other TRAD
Other Specify:
Germany
MA
TRAD
Other TRAD
Other Specify:
Greece
MA
TRAD
Other TRAD
Other Specify:
Hungary
MA
TRAD
Other TRAD
Other Specify:
Iceland
MA
TRAD
Other TRAD
Other Specify:
Ireland
MA
TRAD
Other TRAD
Other Specify:
Italy
MA
TRAD
Other TRAD
Other Specify:
Latvia
MA
TRAD
Other TRAD
Other Specify:
Liechtenstein
MA
TRAD
Other TRAD
Other Specify:
Lithuania
MA
TRAD
Other TRAD
Other Specify:
Luxemburg
MA
TRAD
Other TRAD
Other Specify:
Malta
MA
TRAD
Other TRAD
Other Specify:
The Netherlands
MA
TRAD
Other TRAD
Other Specify:
Norway
MA
TRAD
Other TRAD
Other Specify:
Poland
MA
TRAD
Other TRAD
Other Specify:
food supplements
food supplements
no products
Page 29/120
Member State
Regulatory Status
Comments
Portugal
MA
TRAD
Other TRAD
Other Specify:
Romania
MA
TRAD
Other TRAD
Other Specify:
Slovak Republic
MA
TRAD
Other TRAD
Other Specify:
Slovenia
MA
TRAD
Other TRAD
Other Specify:
Spain
MA
TRAD
Other TRAD
Other Specify:
Sweden
MA
TRAD
Other TRAD
Other Specify:
United Kingdom
MA
TRAD
Other TRAD
Other Specify:
no products
Ginkgo biloba leaf tincture (1:5); extraction solvent ethanol 60% (V/V)
Ginkgo biloba leaf dry extract, refined (39.6-49.5:1), containing 22.0-27.0% of flavonoids
expressed as flavone glycosides, 2.8-3.4% of ginkgolides A, B and C, 2.6-3.2% of bilobalide;
extraction solvent: Ethanol 50% (V/V)
The tincture of Ginkgo biloba leaves is less then 30 years on the market and consequently the above
mentioned products can not be considered for the monograph because a tradition could not be proved.
Page 30/120
For a herbal preparation reported to be marketed in Poland (Ginkgo biloba leaf dry extract, refined
(39.6-49.5:1), containing 22.0-27.0% of flavonoids expressed as flavone glycosides, 2.8-3.4% of
ginkgolides A, B and C, 2.6-3.2% of bilobalide; extraction solvent: Ethanol 50% (V/V)) the tradition for
30 years was not regarded to be established initially the extract was not refined, further steps were
introduced during 80ies and 90ies in order to achieve quantification and the composition of the
relevant preparation changed.
Page 31/120
WHO monograph (1999) referred to the Commission E monograph on refined and quantified extract
of Ginkgo biloba leaves.
DeFeudis (1998) reported that the internal use of Ginkgo biloba leaves for medical purposes was first
mentioned by Liu Wen-Tai in the Ben Cao Pin Hue Jing Yaor (1505 A.D). In modern Chinese
pharmacopoeias Ginkgo biloba is used for treating dysfunctions of the heart and lungs. The leaves are
prescribed for atherosclerosis, angina pectoris, high serum cholesterol levels, dysentery and filariasis
as they improve blood circulation, benefit the brain, and are astringent to the lungs.
3. Non-Clinical Data
Many pharmacological studies have demonstrated that Ginkgo biloba extracts and its constituents
display many properties in vivo and in vitro. A systematic review of all these studies was not
attempted here, rather a selection of studies with emphasis on studies with relevance for the clinical
efficacy were reviewed (for a more extensive review, see Yoshikawa et al. (1999), Chan et al.
(2007), McKenna et al. (2001) and DeFeudis (1998)). Further findings from pharmacological and
pharmacokinetic studies on humans are available and are discussed in section 4.1.
Yoshikawa (1999) reported the following pharmacological effects of Ginkgo biloba:
DeFeudis (1998):
Effects on behaviour, learning and memory, and recovery from traumatic brain injury
Stress-alleviating action
Actions on transmembrane ion channels, ionic shifts, and electrical activity of single cells
Page 32/120
Page 33/120
nor ginkgo leaf extract (n=4). After the operation memory and motor functions were tested for over 80
days. Spatial memory was tested with an 8-arm radial maze test and motor function was tested using
two parameters (locomotor activity and the muscle force of the hind limbs). The results indicate that
both Ginkgo biloba extracts improved spatial memory from the second week after operation, but only
EGb 761 delayed deterioration of motor functions from the fifth week after operation.
Li et al. (2003) investigated hippocampal neuron survival/growth and gene expression after prenatal
exposure of rats to EGb 761. Pregnant rats received orally administered EGb 761 (100 or
300 mg/kg/day) for 5 days (HED=16 or 48 mg/kg, which correspond to 960 or 2880 mg per single
dose in a 60 kg human being). The number of hippocampal neurons of their fetuses increased.
Moreover, it was shown that treatment of pregnant rats with EGb 761 (25, 50 or 100 mg/kg/day for 5
days) altered the expression of 187 genes in the hippocampi of male fetuses and 160 genes in those of
female fetuses. Using gene-cluster analysis, these genes were grouped into 18 distinct clusters for
males and 17 distinct clusters for females. Among these clusters, 35 genes shared a common
expression pattern in male and female hippocampal development. Of these genes, changes were
confirmed by quantitative real-time polymerase chain reaction (PCR) for genes that are mainly
involved in neuronal development, maturation and repair. These molecular and genetic results indicate
that EGb 761 increase neuronal survival and alter the expression of specific genes in the developing
hippocampus.
In the review by Chan et al. (2007) it is stated that Ginkgo biloba leave extract can protect against
the effects of neural damage. It is unclear whether the neuroprotection is from a direct action on the
neurons or from an indirect effect from modulation of blood flow and antioxidant action. When Ginkgo
biloba leave extract was injected (no route of administration or concentration is stated in the review)
into rats after global forebrain ischemia, local cerebral blood flow was significantly elevated.
Furthermore, Ginkgo biloba leaf extract can improve blood flow by increasing red blood cell
deformability and decreasing red cell aggregation, and thus, improves red blood cell fluidity and
decreases whole blood viscosity (no route of administration or concentration is stated in the review).
Inhibitory action on PAF
Koch (2005) confirmed the results of Akiba et al. (1998) principally in a more recent study. The PAFantagonistic activities of individual ginkgolides and EGb 761 were evaluated in rabbit platelets. PAFmediated aggregation of human platelets was half-maximally inhibited (IC 50 ) by ginkgolide A, B, C and
EGb 761 at concentrations of 13.7, 1.6, 33.2 M and 23.2 g/ml, respectively. Of the ginkgolides
tested, ginkgolide B exerted by far the most powerful antagonistic effect.
Akiba et al. (1998) investigated the effect of Ginkgo biloba leaf extract on rabbit platelet
aggregation. Purified ginkgolide A, B and C, which are known to be potent platelet-activating factor
(PAF) receptor-antagonists, apparently inhibited PAF-induced platelet aggregation, but not oxidantinduced aggregation. An extract of Ginkgo biloba leaves (24% flavonol glycosides and 6% terpene
lactones (2.4% bilobalide and 2, 0.8, and 1% ginkgolides A, B, and C, respectively)) also inhibited
PAF-induced platelet aggregation. The IC 50 for ginkgolide A, B, C and the extract were determined to
be 1.8, 0.5, 32 M and 31 g/ml, respectively.
Page 34/120
the extract may involve their antioxidant activity and their ability to inhibit both inducible and
endothelial forms of nitric oxide synthase. Flavonol glycoside and terpene lactone constituents of
ginkgo extracts may act in a complementary manner to inhibit several carcinogenesis-related
processes, and therefore the total extracts may be required for producing optimal effects.
Page 35/120
or breathing rate. Heart rate was increased by 9% at the high dose. Analogue to these results, no
effects on blood pressure, heart and breathing frequency were gained in rabbits.
Oppositional results were observed in rats and guinea pigs. In rats, at the low (330 g/kg) and high
dose (3.3 mg/kg) blood pressure increased by 6 and 28%, respectively for about 13 min with a low
rise of heart rate (7%) and a more pronounced rise in breathing rate (13 and 10%, respectively). In
guinea pigs, an initial short increase on blood pressure (7%) at the low dose was observed followed by
a decrease of 23% for 11 min. Heart rate dropped by 11% and breathing rate increased by 56%. A 10fold higher dose caused at first increase in blood pressure (48%) for 3 min and a subsequent decrease
of 21% for about 13 min. This was accompanied by reduction in heart rate of 16% for 15 min and a
rise in breathing rate of 48%. The increase in breathing rate was affected by intravenous injection
itself and not by the specific effect of the ginkgo preparation. This was shown in control experiments
with the same amount of physiological sodium chloride solution.
Experiments with only Cremophor EL resulted in a rise of blood pressure (between 20 and 50%), heart
frequency (8%) and breathing rate (100%).
Brunello et al. (1985) Oral treatment of rats with EGb 761 (100 mg/kg/day, p.o., HED for a 60 kg
human=968 mg/day) elicited a biphasic effect on the norepinephrine metabolite normetanephrine
(NMN) content in the cerebral cortex: An initial decrease was evident after 45 min. followed by a
marked increase that was evident after 14 days. Chronic treatment with EGb 761 reduced the density
of -adrenoceptor (no subtype specified) binding to cerebral cortex and -adrenergic-stimulated
adenylate cyclase activity after 2 months. Thus, an increase in norepinephrine levels is inducing adrenergic receptor regulation and functional activity.
Kehr et al. (2012) The effect of repeated oral administration of EGb 761 and some of its
characteristic constituents on extracellular levels of dopamine (DA), noradrenaline (NA), serotonin (5HT), acetylcholine (ACh) and the metabolites 3,4- dihydroxyphenylacetic acid (DOPAC), homovanillic
acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in the medial prefrontal cortex (mPFC) of awake
rats was investigated by use of in vivo microdialysis technique. Subacute (14 days, once daily), but not
acute, oral treatment with EGb 761 (100 and 300 mg/kg) or the flavonoid fraction, which represents
about 24% of the whole extract caused a significant and dose-dependent increase in extracellular DA
levels in the mPFC. Repeated administration of EGb 761 also caused a modest but significant increase
in the NA levels, whereas the concentrations of 5-HT and those of the metabolites DOPAC, HVA and 5HIAA were not affected. The same treatment regimen was used in a subsequent study with the aim of
investigating the effects of two Ginkgo-specific acylated flavonols, 3-O- (2-O-(6-O-(p-hydroxytrans-cinnamoyl)--D-glucosyl)--L-rhamnosyl)quercetin (Q-ag) and 3-O-(2- O-(6-O-(p-hydroxytrans-cinnamoyl)--D-glucosyl)--L-rhamnosyl)kaempferol (K-ag). Both compounds together represent
about 4.5% of the whole extract. Repeated oral treatment with Q-ag (10 mg/kg) for 14 days caused a
significant increase in extracellular DA levels of 159% and extracellular acetylcholine (ACh) levels of
151% compared to controls. Similarly, administration of K-ag (10 mg/kg) induced a significant rise of
DA levels to 142% and ACh levels to 165% of controls, whereas treatment with isorhamnetin, an Omethylated aglycon component of EGb 761 flavonol glycosides had no effect. None of the tested
flavonoids had a significant effect on extracellular DOPAC and HVA levels. The effect on
neurotransmitter levels seems not to be a general effect of flavonols but rather to be a specific action
of acylated flavonol glycosides which are present in EGb 761. The direct involvement of these two
flavonol derivatives in the increase of dopaminergic and cholinergic neurotransmission in the prefrontal
cortex may be one of the underlying mechanisms behind the reported effects of EGb 761 on the
improvement of cognitive function.
Page 36/120
3.2.1. Absorption
Moreau et al. (1986) studied the absorption of radiolabelled
plants grow under supply of
14
14
be at least 60%. A site of absorption in the upper gastrointestinal tract is suspected since specific
radioactivity in blood peaked after 1.5 hours.
3.2.2. Distribution
Moreau et al. (1986) further analysed the distribution of radiolabelled EGb 761. The
pharmacokinetics of the extract, based on blood specific activity data versus time course, were
characteristic of a two-compartment model with an apparent first order phase and a biological half-life
of approximately 4.5 hours. During the first 3 hours, radioactivity was preliminary associated with the
plasma, but through a gradual uptake after 48 hours. The specific activity in erythrocytes matched that
of plasma. Glandular and neuronal tissues and eyes showed a high affinity for the labelled substance.
3.2.3. Metabolism
Chatterjee et al. (2005) investigated the effects of EGb 761 on hepatic CYP450 in rats (no subtypes
mentioned). Oral administration of EGb 761 (100 mg/kg/day, HED for a 60 kg human=968 mg/day)
for 4 days strongly increased liver CYP450 content and altered the ex-vivo biotransformation of
androstendione, as well as metabolism of endogenous steroids. However, no effect on the urinary
steroid profile was observed in man after intake of 240 mg/day EGb 761 for 28 days. In view of these
results, the authors concluded that the effects of EGb 761 on drug metabolism enzymes are specific for
rats and may not be extrapolated to man.
Gaudineau et al. (2004): The following study was conducted to examine the inhibition of CYP1A2,
CYP2C9, CYP2D6, CYP2E1, and CYP3A4 by EGb 761 and its constituents. As a general observation,
EGb 761 inhibited all the P450s studied except CYP2D6 (K i >900 g/ml). The activity of CYP2C9 was
the most affected by EGb 761 (K i =144 g/ml). CYP1A2 (10624 g/ml), CYP2E1 (12742 g/ml),
and CYP3A4 (15543 g/ml) were also inhibited but to a lesser extent. The terpenoidic fraction
inhibited only CYP2C9 (K i =156 g/ml) whereas the flavonoidic fraction of EGb 761 showed high
inhibition of CYP2C9, CYP1A2, CYP2E1, and CYP3A4 (K i s between 4.9 and 55 g/ml).
Von Moltke et al. (2004): The in vitro study was used to determine whether any of 29 constituents
of Ginkgo biloba can be considered as potentially important inhibitors of any of the five major CYP
isoforms in human liver microsomes. Significant inhibitory activity was observed for the flavonol
aglycones (kaempferol, quercetin, apigenin, 4-OH-methyl apigenin, myricetin, tamarixetin), which
Page 37/120
yielded IC 50 values for CYP1A2 or CYP3A of less than 10 g/ml. Quercetin was also a strong inhibitor of
CYP2C9 (IC 50 =7.8 g/ml, 25.8 M), as was myricetin for CYP2D6 (IC 50 =9.6 g/ml, 30.2 M). An
inhibitory effect on CYP2C9 and CYP3A was also observed for amentoflavone, sesamin, (Z,Z)-4,4(1,4-pentadiene-1,5-diyl)diphenol and 3-nonadec-8-enyl-benzene-1,2-diol. The principal components
of Ginkgo biloba (terpene lactones and flavonol glycosides) showed no significant inhibition of these
human CYPs in vitro. It was concluded that a number of flavonol aglycones, as well as the biflavonol
amentoflavone, are inhibitors of several human CYP isoforms in vitro. Inhibition of CYP2C9 is of
potential concern, since this enzyme is responsible for clearance of some drugs (such as S-warfarin)
that have narrow therapeutic ranges in clinical practice. The importance of the in vitro findings requires
evaluation in clinical studies.
3.2.4. Elimination
Moreau et al. (1986) examined beside the absorption and distribution also the elimination of
radiolabelled EGb 761. Three hours after oral administration of the extract to rats expired
14
C-CO 2
represented 16% of the administered dose and 38% after 72 hours. Further 21% were eliminated in
the urine and 29% in faeces.
Page 38/120
cells). Ginkgo biloba inhibited CYP3A4 activity (IC 50 value of 66866 g/ml) and P-gp activity (IC 50
value of 23.6 g/ml). The low IC 50 value for Ginkgo biloba may indicate an inhibition of P-gp in the
small intestine in vivo.
Page 39/120
rifampin, could increase the cytotoxicity of ginkgolic acid in HepG2 cells. These results suggest that
HepG2 cells were more sensitive to the cytotoxicity of ginkgolic acid than primary rat hepatocytes, and
CYP1A and CYP3A could metabolise ginkgolic acid to more toxic compounds.
3.3.3. Genotoxicity
A Ginkgo biloba leaf extract was tested positive for gene mutations in bacteria and equivocal and
negative for chromosome mutations in two separate in vivo tests in peripheral erythrocytes and bone
marrow cells in mouse. ( NTP Technical report 578, 2013)
3.3.4. Carcinogenicity
Major findings from NTP report:
NTP Technical report 578 (2013) has tested a Gingko biloba leaf extract for carcinogenesis in two year
studies in rats and mice.
Page 40/120
Summarising the major findings of the NTP Technical report, rodents dosed with Ginkgo biloba extract
showed increased rates of a variety of lesions in the liver, thyroid gland, and nose. These lesions
included hypertrophy in the liver and thyroid gland in rats and mice, liver hyperplasia in male and
female rats, hyperplasia and atrophy of the epithelium in the nose of male and female rats.
Increased incidences of cancers of the thyroid gland were seen in female rats and liver cancers in male
and female mice.
Mononuclear cell leukemia was observed in male rats at 300 and 1000 mg/kg. The increased incidence
of mononuclear cell leukemia in rats is probably a background finding, as this strain of rats has a
highly variable background rate for this tumor.
View of the HMPC based on a detailed assessment of the NTP technical report with respect to the
development of a monograph:
No carcinogenicity was observed in the nose, but benign respiratory epithelium tumours (adenoma)
were observed in 2 female rats at the intermediate dose level (300 mg/kg). The occurrence of
adenoma did not show a dose response and occurred in one sex only. However, there were dosedependent morphological changes in the nose. It should be noted that these lesions may have been
secondary effects from oesophageal reflux due to gavage application and/or a secondary effect to
repeated irritant and inflammatory stimulation. To be able to draw a definitive conclusion of the nose
findings additional information from the pathology report would be needed. Induction of CYP 450
enzymes in the nose may also have contributed to these lesions. The mechanism of the non-neoplastic
lesions in the nose in rodents has not been fully established, and therefore the risk to humans cannot
be finally assessed. However, the proposed explanations are plausible and there was no increase of
neoplastic changes. Thus, these findings are considered of limited relevance for human safety.
Carcinogenic effects associated with Ginkgo biloba extract administration are mostly characteristic of
lesions related to hepatic enzyme induction. Carcinogenic activity of Ginkgo biloba extract in liver was
more pronounced in mice than rats. The relation of thyroid lesions to increased metabolic activity in
liver is well known in rodents, and rats are especially sensitive to that mechanism which is in
correlation to study results where hepatic effects were more severe in mice that in rats, but thyroid
effects were more pronounced in rats (Hernandez et al. 2009, Li et al. 2009, Silva Lima & van der Laan
2000).
In principle the lesion in thyroid and liver are considered due to promotion by thyroid and liver enzyme
induction and not due a genotoxic mode action.
Effects seen in nose olfactory and respiratory epithelium in rat and mouse might be considered related
to secondary effects from oesophageal reflux due to gavage application or to induction of metabolising
enzymes and be a secondary effect to repeated irritant and inflammatory stimulation or enzyme
induction via systemic exposure. Furthermore only adenomas occurred and only in the 300 mg/kg dose
female group. However as exposure data of the nasal epithelium are missing there are not enough
data for a final conclusion.
Mononuclear cell leukemia observed in the 2-year carcinogenicity study in rats given Ginkgo biloba
might be considered a background finding and is considered of limited relevance to humans.
The NTP studies do not provide evidence for an increased cancer risk following the use of Ginkgo biloba
extracts at the approved posology. There is plausible evidence for the main effects in liver and thyroid
gland to be caused by rodent specific mechanisms not relevant for humans. For the morphological
changes in the olfactory epithelium in female rats, amechanistic explanation has not been
demonstrated, although there are plausible explanations proposed. The MCLs in male rats are
considered of limited relevance to humans. These effects however were not seen in the low dose
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 41/120
groups providing margins of exposure of at least 5 to 6 compared to the NOEL for these effects based
on a mg/m2 calculation of the human equivalent dose.
Conclusion:
At present there is no proof for an increased cancer risk identified for patients taking Ginkgo medicinal
products at their approved posology.
Page 42/120
significant reduction in the rate of oocyte maturation, fertilisation, and in vitro embryonic development.
Treatment of oocytes with 1-6 M ginkgolide B during in vitro maturation led to increased resorption of
postimplantation embryos and decreased placental and fetal weights. Data obtained using an in vivo
mouse model further disclosed that consumption of drinking water containing 3-6 M (estimated daily
intake is 325-625 g/kg with a HED of 29-55 g/kg, versus human daily intake of 130 g/kg)
ginkgolide B led to decreased oocyte maturation and in vitro fertilisation, as well as early embryo
development injury, specifically, inhibition of development to the blastocyst stage in vivo.
Chan (2005) showed that ginkgolide A and ginkgolide B treatment (both 5 and 10 M) of mouse
blastocysts induces apoptosis, decreases cell numbers, retards early postimplantation blastocyst
development, and increases early-stage blastocyst death in vitro.
Baron-Ruppert and Luepke (2001) assessed the adverse properties of alkylphenols in different
fractions, gained as water insoluble compounds (decanter sludge) during production of EGb 761, for
their embryotoxic effects in the hens egg test (HET). A fraction enriched for ginkgolic acids (16%) and
biflavones (6.7%) was found to induce death of 50% of the chick embryos (LD 50 ) at a dose of
1.8 mg/egg (approx. 33 ppm). A similar strong lethal effect was observed for a fraction which
contained 58% ginkgolic acids but less than 0.02% biflavones with LD 50 at a dose of 3.5 mg/egg
(64 ppm). In contrast, an extreme low toxic potential was shown in a fraction containing 1% ginkgolic
acids and 16% biflavones with LD 50 at 250 mg/egg or 4540 ppm. Thus, the present investigation
confirms the high toxic potential of ginkgolic acids, although it cannot be excluded that biflavones or
some other constituents in the different fractions may amplify the adverse effect of these substances.
Since no contribution of alkylphenols to the therapeutic efficacy of Ginkgo biloba extracts has been
confirmed and their elimination during the manufacturing process does not cause technical problems,
the authors concluded that these results further support the requirement for the completest possible
removal of these compounds under toxicological considerations.
Floissac and Chopin (1999): The effect of Ginkgo biloba on embryological development in chick
embryos was the subject of this article. Fertile chick eggs (n=387) were injected with one of five
dosages of Ginkgo biloba (not further specified) diluted in physiological saline. The Ginkgo biloba doses
were equivalent to single human doses of 20, 40, 80, 120, and 240 mg. Control eggs (n=74) received
physiological saline only. On developmental day 7, the embryos were examined for viability and
malformations. A trend to decreasing viability with increasing Ginkgo biloba dosage was observed, but
the trend was not statistically significant. Increasing dosages of Ginkgo biloba were accompanied by
increasing frequencies of malformations particularly subcutaneous bleeding. Embryos exposed to the
three highest dosages of Ginkgo biloba had statistically significant increases in total malformations
(p<0.05) and subcutaneous bleeding (p<0.05). These dosages represented the suggested daily dose
range for adults. In conclusion it was stated, that Ginkgo biloba should be used with caution during
pregnancy.
Fernandes et al. (2010) verified whether an aqueous Ginkgo biloba extract (manufactured in Brazil
with the following composition: 28.2% flavonoid glycosides; 8.3% terpene lactones; 15% quercetin;
10.9% kaempferol; 2.3% isorhamnetin; 1.4% ginkgolide A; 1.1% ginkgolide B; 3.0% ginkgolide C;
0.9% ginkgolide J; 0.7% bilobalide and less than 5 ppm (0.81%) of ginkgolic acids) affects embryonic
development when administered to pregnant rats during the one-cell-to-blastocyst period, which
includes the phase of tubal transit and implantation. Pregnant rats received 0, 3.5, 7.0 and
14.0 mg/kg/day of aqueous Ginkgo biloba extract by gavage, from the 1st to the 8th day of pregnancy.
No significant toxic effect was found on the maternal organism and for embryonic parameters.
Zehra et al. (2010) determined gross structural malformations to the mice fetuses of the mothers
given a standardised Ginkgo biloba extract (not further specified) during pregnancy. Pregnant females
were divided into three groups (A, B and C), of 6 mice each. The two experimental groups A and B
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 43/120
received 78 and 100 mg/kg/day, respectively, whereas group C served as control. Both experimental
groups were given the drug orally throughout the gestational period. The animals were sacrified on the
18th day of gestation. Forty-nine fetuses from groups B and C and 50 fetuses from group A were
recovered. There was a significant (p<0.05) decrease in weight and crown-rump length of fetuses in
group B as compared to those from group A and C. Further, fetuses from groups A and C did not show
any gross abnormalities, whereas those from group B exhibited a high frequency of malformations
including round shaped eye and orbits (48%), syndactyly (40.8%), malformed pinnae (44.1%),
nostrils, lips and jaws (all three together 42.8%). These results indicate that Ginkgo biloba extract is
harmful to the developing fetuses in vivo.
Pinto et al. (2007) evaluated the effects of a Ginkgo biloba extract (composed of 28.2% of
ginkgoflavonglycosides; 8.3% of terpene lactones; 15% of quercetin glycosides; 10.9% of kaempferol
glycosides; 2.3% of isorhamnetin glycosides and less than 5 ppm of ginkgolic acids) during the periods
of organogenesis and fetogenesis. 0, 3.5, 7 and 14 mg/kg body weight/day Ginkgo biloba extract was
administered orally in 1 ml of aqueous solution to pregnant rats from the 8th to 20th day of pregnancy.
After killing the rats on the 21st day the following parameters were evaluated: maternal body weight;
food and water intake; maternals liver, kidney and ovary weights; resorption index; post-implantation
loss; mean of live fetuses; fetuses and placenta mean weight; fetusesliver, kidney, lung and brain
weights; fetusesexternal malformations. The maternal parameters of toxicity did not changed
significantly, whereas the treatment Ginkgo biloba extract resulted in a significant decrease in the
fetuses mean weights. The results suggest that Gingko biloba extract administration with 7 and
14 mg/kg/day to rats in the organogenic and fetogenic periods can lead to fetal intra-uterine growth
retardation, although it did not cause maternal toxicity.
Amin et al. (2012) assessed the protective effects of Ginkgo biloba extract (GBE, purchased from
General Nutrition Corporation, Pittsburgh, USA) against chemotherapeutic-induced reproductive
toxicity using a data mining tool, namely Neural Network Clustering (NNC) on two types of data:
biochemical & fertility indicators and Texture Analysis (TA) parameters. GBE (1 g/kg/day,
HED=9677 mg per daily dose) was given orally to male albino rats for 26 days. This period began 21
days before a single cisplatin (CIS) intraperitoneal injection (10 mg/kg body weight). GBE given orally
significantly restored reproductive function. Tested extract also notably reduced the CIS-induced
reproductive toxicity, as evidenced by restoring normal morphology of testes. In GBE treated mice the
attenuation of CIS-induced damage was associated with less apoptotic cell death both in the testicular
tissue and in the sperms. CIS-induced alterations of testicular lipid peroxidation were markedly
improved by the examined plant extract. NNC has been used for classifying animal groups based on
the quantified biochemical & fertility indicators and microscopic image texture parameters extracted by
TA. NNC showed the separation of two clusters and the distribution of groups among them in a way
that signifies the dose-dependent protective effect of GBE.
Al-Yahya et al. (2006): The effects of Ginkgo biloba (50 mg tablet contains 50 mg of Ginkgo biloba
extract and 12 mg of ginkgo flavone glycosides, which correlates to 24%) on reproductive, cytological
and biochemical toxicity was evaluated in Swiss albino mice. The mice received 25, 50 or
100 mg/kg/day oral doses of an aqueous suspension of Ginkgo biloba for 90 days. The following
parameters were evaluated: reproductive organ weight; motility and content of sperms; spermatozoa
morphology; cytology of the testes chromosomes; study on reproduction; biochemical study on
proteins, nucleic acids, malondialdehyde (MDA) and nonprotein sulfhydryl (NP-SH). Significant changes
were observed in the weight of caudae epididymis, prostate, chromosomal aberrations, rate of
pregnancy and pre-implantation loss. The evaluation of biochemical parameters showed depletion of
nucleic acids, NP-SH and increase of MDA, which elucidated the role of free radical species in the
induced changes in testis chromosomes and the reproductive function.
Page 44/120
Ondrizek et al. (1999a) analysed the effect of Ginkgo biloba (not further specified) at 0.1 and
1 mg/ml on sperm DNA and on the fertilisation process. Zona-free hamster oocytes were incubated for
1 hour in Ginkgo biloba or control medium before sperm-oocyte interaction. The DNA of Ginkgo bilobatreated sperm was analysed with denaturing gradient gel electrophoresis. Oocyte penetration and
integrity of the sperm BRCA1 exon 11 gene were measured as main outcomes. The results show that
high concentrations of Ginkgo biloba could inhibit the penetration of oocytes by sperm. The oocytes
treated with Ginkgo biloba were visibly degenerated. There was abnormally high sperm binding on the
oocyte surface. The lower concentration of Ginkgo biloba produced a numerically lower percentage of
penetration, although this was not significant. Antioxidants have been used to prevent oxidative
damage to cellular membranes. In this case, however, the antioxidant property of this herb did not
help improve sperm penetration. Exposure of sperm to Ginkgo biloba had no effect on DNA
denaturation.
Ondrizek et al. (1999b) analysed sperm motility parameters in the presence of Ginkgo biloba (not
further specified) at 0.12 and 1.2 mg/ml. Sperm were incubated in Ginkgo biloba or control medium
and parameters were measured on a Hamilton-Thorn analyser after 1, 4, 24 and 48 hour at 37C.
There were no significant differences in the motility and the kinematic parameters on Ginkgo biloba
versus the control at the low concentration tested. However, when the concentration of Ginkgo biloba
was increased sperm motility was inhibited at 24 and 48 hours. Sperm curvilinear velocities were lower
after 24 and 48 hours in the high concentration of Ginkgo biloba compared with the control. There
were no differences in the other remaining kinematic parameters (Hyperactivation and beat cross
frequency) for the high concentrations of Ginkgo biloba.
Page 45/120
Page 46/120
An in vitro study indicates that EGb 761 inhibits activity of CYP1A2, CYP2C9, CYP2E1 and CYP 3A4, in
which the activity of CYP2C9 was the most affected. Another in vitro study with an ethanolic Ginkgo
biloba extract supports the inhibitory effect on CYP3A4 activity and proposes also an inhibitory effect
on P-gp activity. In vivo studies in animals confirmed inhibition activity of Ginkgo biloba leaf extract on
CYP3A4. Nervertheless, some interaction that occurred in the animal assays could not be extrapolated
to humans.
Toxicology
A study report on a carcinogenesis study with a Ginkgo biloba extract (different from the Pharm. Eur.
Specification but nevertheless similar) in rats and mice for two years raised questions about possible
carcinogenic effects.
The NTP studies do not provide conclusive evidence for an increased cancer risk for the use of Ginkgo
biloba extracts at the recommended doses. There is plausible evidence for the main effects in liver and
thyroid gland to be caused by rodent specific mechanisms not relevant for humans. For adenomas in
olfactory epithelium in rats and MCLs in male rats a conclusive mechanistic explanation is currently not
provided. These effects however were not seen in the low dose groups providing margins of exposure
of at least 5 to 6 compared to the NOEL for these effects based on a mg/m2 calculation of the human
equivalent dose.
It can be concluded that at present there is no proof for an increased cancer risk identified for patients
taking Ginkgo medicinal products at their approved posology.
However as any potential of Ginkgo biloba extracts for inducing gene mutations in vivo cannot be
excluded due to missing of such data and as there are significant differences in the extract tested in
the NTP study and the extract EGb 761, mostly marketed in pharmaceuticals in Europe, with respect to
exposure to ginkgolides (LPT Report No. 29879, 2013) in mice, data of in vivo gene mutation assays in
target organs of carcinogenesis in mice for Ginkgo biloba extracts are considered necessary to fully
exclude any in vivo mutagenic potential of Ginkgo biloba extracts to be involved in the induction of
tumors in rodents and further exclude any relevance for human use.
Limited studies concerning single dose and repeated dose toxicity, as well as local tolerance are
mentioned above as there is sufficient and well-documented experience available in humans (see
section clinical data).
The results show LD 50 values for mice and rats for single dose toxicity. With 7.73, 1.1 and 1.9 g/kg for
mice and >10, 1.1 and 2.1 g/kg for rats by oral, i.v. and i.p. EGb 761 administration, respectively.
Furthermore, no evidence of organ damage or impairment of hepatic and renal functions by chronic
EGb 761 administration in rats, mice and dogs was observed. The data of single dose and repeated
dose toxicity of isolated compounds are administered in much higher doses than clinically relevant.
Most of the available reproductive and developmental toxicity studies are conducted with Ginkgo biloba
extracts different from the monograph relevant extract or with single components present in Ginkgo
biloba extracts. The studies are conducted in vitro as well as in vivo in mice, rats, rabbits and chicken.
The results of a current investigation showed a dose-dependent ovarian toxic effect of EGb 761 in rats
at HED: 20-80 mg per daily dose. The effect on fertility was represented by significantly reduced
ovarian follicle counts, resorption index, implantation index and fetal viability. In contrast to these
results, older studies indicate no teratogenic effects or reproductive toxicity of EGb 761 orally
administered to rats (100, 400 or 1600 mg/kg/day) and to rabbits (100, 300 or 900 mg/kg/day).
In vitro and in vivo studies conducted with single components of Ginkgo biloba (ginkgolide A and B
with a HED of 29-55 g/kg versus a human daily intake of 130 g/kg) indicated significant reduction
on oocyte maturation, fertilisation and embryonic blastocysts development. The high toxic potential of
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 47/120
ginkgolic acids and the following completest possible elimination during manufacturing ginkgo extracts
was confirmed in an in vivo study.
There is evidence that ginkgo containing preparations can increase the disposition for bleeding.
Therefore, Ginkgo biloba leaf dry extract must not be used during pregnancy.
Contrary results are reported in two studies regarding the effect of Ginkgo biloba extracts on
embryonic development (day 0-18 and 0-20, respectively). High dose administration of EGb 761 (HED:
1935 mg/kg per daily dose) caused no toxicity on maternal or fetal-placental data compared to low
dose administration of a not specified Ginkgo biloba extract (HED: 417 and 535 mg/kg per daily dose)
which caused high frequency (40-48%) of structural malformations. Another study supports harmful
effects of ginkgo containing extracts on embryonic development. A low dose (HED: 68 and 135 mg/kg
per daily dose) given from day 8-20 of pregnancy showed also toxic effects on embryonic
development. Whereas no developmental toxic effects were found in a study from day 1-8 of
pregnancy at low doses (HED: 33, 68, 135 mg/kg per daily dose).
Further, a protective effect of ginkgo containing extracts against chemotherapeutic-induced
reproductive toxicity was observed.
In summary, a lot of pharmacological, pharmacokinetic and toxicological studies conducted with
preparations of Ginkgo biloba leaf extract and its constituents exist. In considering the abovementioned pharmacological data, clinical findings and derived indications for a well-established use can
be supported by these studies. Pharmacokinetic studies of Ginkgo biloba leaf preparations and its
constituents are available and give an evidence for numerical quantity values and bioavailability.
Adequate toxicological data are mentioned, but for one, with no clinical relevance. As for these studies,
which were performed, either no specific characterised extract was used or the applied doses were
higher than the highest corresponding human dose of 120-240 mg or ginkgolic acids values were
higher than those applied in clinical use, since the declaration of the Ginkgo biloba leaf extract in the
Ph. Eur. states a maximum value of 5 ppm of ginkgolic acids.
4. Clinical Data
4.1. Clinical Pharmacology
4.1.1. Overview of pharmacodynamic data regarding the herbal
substance(s)/preparation(s) including data on relevant constituents
4.1.1.1. Primary pharmacodynamics
Effect on cognition
Gener et al. (1985): In a double-blind trail 60 volunteers (57-77 years) with age-related mental
deterioration participated to estimate the action of EGb 761 on the central nervous system.
Quantitative pharmaco-electroencephalography (EEG) was used to assess the vigilance-promoting
effects of the drug. Subjects were divided into three groups (n=20 in each group) and received
randomly 3x40 mg/day EGb 761, 5 mg nicergoline or placebo. Analysis of the whole group for vigilance
revealed no significant advantage of EGb 761 over the two reference substances. However, a
subclassification of the subjects showed that the vigilance of those persons with a more unfavourable
initial situation measured in the resting EEG could be clearly improved by chronic EGb 761 medication.
This increase in vigilance was reflected at the behavioural level by an improvement of reaction times
compared with the reference substances. These results show that chronic EGb 761 medication has a
positive effect in geriatric subjects with deterioration of mental performance and vigilance, and this
Page 48/120
effect is reflected at the behavioural level. In contrast, healthy subjects with a good initial state
achieve hardly any improvement.
Elsabagh et al. (2005) conducted a placebo-controlled and double-blind study to compare the effects
of LI 1370 after acute and chronic treatment on tests of attention, memory and executive function in
92 healthy subjects (18-26 years). Participants were randomly allocated to receive a single dose of
LI 1370 (120 mg, n=26) or placebo (n=26). Another 40 were randomly allocated to receive LI 1370
(120 mg/day, n=20) or placebo (n=20) for a 6-week period. The acute dose of LI 1370 significantly
improved performance on the sustained-attention task and patter-recognition memory task; however,
there were no effects on working memory, planning, mental flexibility or mood. After 6 weeks of
treatment, there were no significant effects of LI 1370 on mood or any of the cognitive tests. In
conclusion, performance in tests of attention and memory was improved after acute administration of
LI 1370. However, there were no effects after 6 weeks, indicating that tolerance develops to the
effects in young, healthy subjects.
Santos et al. (2003) performed a double-blind, placebo-controlled study with 48 healthy men (60-70
years). Participants randomly received oral 80 mg/day dried Ginkgo biloba extract (produced by Maze
Produtos Qumicos e Farmaceuticos Ltda., 100 mg contained 24% flavonoide, 6.1% terpenoide, 2.7%
bilobalide, 1.7% ginkgolide A, 0.9% ginkgolide B, and 0.8% ginkgolide C) or placebo for a period of 8
months. Evaluation of cognitive alterations was based on a number of neuropsychological tests
including single photon emission computer tomography (SPECT) and measures of blood viscosity. The
experimental group showed a reduction in blood viscosity, improved cerebral perfusion in specific areas
and improved global cognitive functioning. In contrast, these parameters were opposite in the control
group. These results suggest that Ginkgo biloba dry extract appears to be effective in the treatment of
cognitive deficits in elderly.
Effect on blood flow
Guinot et al. (1989): An open study was conducted to examine the antagonistic activity of EGb 761
on PAF-induced platelet aggregation. 6 healthy volunteers received a single oral administration of
15 ml liquid extract (dose not indicated). Ex vivo platelet aggregation was determined by
aggregometry on platelet-rich plasma. There was a reduction in platelet aggregation at all doses of
PAF, as well as with 1 M ADP and adrenaline. The most significant decreases occurred with 75 nM PAF
4 hours after intake (p<0.05) and 300 nM 4 (p<0.01) and 8 hours after intake (p<0.05). There were
no concomitant changes in coagulation, skin bleeding time, haematological and biochemical laboratory
tests, blood pressure or pulse. The results provide a possible explanation for the clinical efficacy of
EGb 761 in the treatment of peripheral vascular disease.
Mehlsen et al. (2002) examined possible vasodilating effects of a Ginkgo biloba extract (Gibidyl
Forte, produced in Denmark, containing 9.6 mg ginkgoflavonglycosides and 2.4 mg terpenlactones per
tablet) on forearm haemodynamics. 16 healthy subjects with a median age of 32 years (range: 21-47)
received three tablets daily of Ginkgo biloba or placebo. The study was performed in a randomised,
double-blind, cross-over design for 6 weeks. Forearm blood flow was significantly higher during active
treatment after 3 and 6 weeks as compared with placebo treatment for 3 and 6 weeks (p<0.05). Mean
arterial blood pressure was unchanged, making the calculated FVR significantly lower during active
treatment (p<0.02). It was concluded that oral treatment with a Ginkgo biloba extract (Gibidyl Forte)
is able to dilate forearm blood vessels causing increments in regional blood flow without changing
blood pressure levels in healthy subjects.
4.1.1.2. Secondary pharmacodynamics
No data available.
Page 49/120
Page 50/120
Ginkgolide B
Bilobalide
C max (ng/ml)
22.22 4.57
8.27 1.82
54.42 13.62
t max (h)
1.17 0.39
1.54 0.50
1.21 0.45
121.35 22.92
59.88 11.39
217.24 44.07
T (h)
3.93 0.40
6.04 1.48
3.19 0.40
Ginkgolide B
Bilobalide
C max (ng/ml)
33.29 9.12
16.46 5.02
18.81 8.84
t max (h)
1.06 0.72
1.17 0.69
1.17 0.80
146 21.50
109.90 20.60
78.97 38.98
T (h)
4.50 1.55
10.57 3.56
3.21 0.64
According to Fourtillan et al. (1995) food intake did not modify bioavailability of ginkgolides A, B and
bilobalide, although their rate of absorption was slowed, as revealed by a delayed T max .
Biber (2003): In a dose-response study, 12 healthy volunteers received 80, 120 and 240 mg
EGb 761 as a solution. The results are shown in table 3.
Table 3. Pharmacokinetic parameters after oral administration of EGb 761 in healthy volunteers
(Biber 2003)
Extract dose
Constituent dose
C max
(mg)
(mg)
(ng/ml)
80
1.056
120
240
T max (h)
T (h)
15.2 2.8
0.61 0.21
69.9 18.4
4.5 2.5
1.584
25.3 9.9
0.60 0.20
103.2 16.3
4.5 1.6
3.168
42.9 9.1
0.75 0.20
211.1 37.6
5.1 1.4
80
0.560
6.53 1.23
1.29 0.62
43.75 8.77
6.5 2.6
120
0.840
9.12 1.48
0.92 0.25
70.03 19.55
8.5 3.0
240
1.680
18.11 4.16
1.21 0.32
140.69 33.62
9.9 2.0
80
2.280
30.2 12.6
0.86 0.40
114.7 56.7
5.5 3.6
120
3.420
35.2 8.3
0.67 0.18
128.1 58.4
4.0 1.7
240
6.840
58.6 19.1
0.72 0.20
247.1 107.1
4.9 2.5
Ginkgolide A
Ginkgolide B
Bilobalide
As reported in the German monograph of the Commission E, the absolute oral bioavailability was 98100% for ginkgolide A, 79-93% for ginkgolide B and > 70% for bilobalide after oral administration of
EGb 761 (Commission E monograph on Ginkgo biloba leaf dry extract, 1994).
Page 51/120
Chan et al. (2007): After an oral dose of EGb 761 (80 mg) maximum plasma levels of ginkgolide A
(C max =15 ng/ml) and ginkgolide B (C max =4 ng/ml) were attained at 1.4-2.0 hours. The half-lives of
ginkgolide A and ginkgolide B were 3.9 and 7 hours.
Woelkart et al. (2010) investigated bioavailability and pharmacokinetics of ginkgo terpene lactones
of three different Ginkgo biloba L. preparations; ginkgo fresh plant tincture, where 1 ml contains the
equivalent of 920 mg Ginkgo biloba leaves as active ingredient (ethanol for extraction, DER=1:9), one
new ginkgo fresh plant extract tablet (250 mg) comprises 90 mg of ginkgo fresh plant extract (ethanol
for extraction, DER=3-5:1) and EGb 761 tablets (40 mg). The study was conducted in a randomised,
open, parallel group design with 24 healthy volunteers. Subjects received a single oral dose of the
different formulations with diverse amounts of terpene trilactones. The applied oral doses were the
corresponding maximum registered daily dose, which is 2512 mg of the tincture, 1000 mg of the fresh
plant extract tabvlets and 120 mg for EGb 761. The results demonstrate relative bioavailability of
different Ginkgo biloba L. preparations.
Table 4. Maximum concentrations (median) of terpene lactones in plasma after administration of
the maximum daily dose of different ginkgo preparations (Woelkart et al. 2010)
Ginkgo plant fresh tincture
EGb 761
Bilobalide
3.53
11.68
26.85
Ginkgolide A
3.62
7.36
16.44
Ginkgolide B
1.38
4.18
9.99
C max (ng/ml)
Wjcicki et al. (1995): The following table shows pharmacokinetic parameters of the flavonol
glycosides quercetin, kaempferol and isorhamnetin after a single administration of EGb 761 (no dose
mentioned) in three different formulations in an equal amount given to 18 volunteers.
Table 5. Pharmacokinetic parameters of flavonol glycosides after a single oral dose of EGb 761 to
healthy subjects (Wjcicki et al. 1995)
Capsules
Drops
Tablets
C max (ng/ml)
12.16 0.60
13.79 0.77
13.45 0.74
t max (h)
2.47 0.05
2.00 0.07
2.00 0.08
63.71 2.99
64.66 3.62
60.15 3.46
C max (ng/ml)
26.73 1.19
30.02 1.28
28.94 1.24
t max (h)
2.44 0.06
2.03 0.08
2.03 0.08
138.43 6.69
138.08 7.08
130.37 6.92
C max (ng/ml)
7.26 0.37
9.62 1.61
7.81 0.31
t max (h)
2.44 0.07
2.03 0.08
2.03 0.08
34.63 1.99
39.99 6.13
31.55 1.89
Quercetin
Kaempferol
Isorhamnetin
Page 52/120
4.1.2.3. Metabolism
Chang et al. (2006): In the following in vitro study the effect of Ginkgo biloba extract constituents on
procarcinogen-bioactivating human CYP1 enzymes was investigated. It was shown that the aglycones
of quercetin, kaempferol, and isorhamnetin inhibited CYP1B1, CYP1A1, and CYP1A2. The most potent
inhibitor of CYP1B1 was isorhamnetin with a K i -value of 30.1 nM, whereas quercetin was with
K i =41850 nM the least potent inhibitor of CYP1A2. Ginkgo biloba extract also reduced
benzo[a]pyrene hydroxylation, and the effect was greater with CYP1B1 than with CYP1A1 as the
catalyst. In summary, these novel findings from the present study indicate that Ginkgo biloba extract
and the flavonol aglycones, isorhamnetin, kaempferol, and quercetin, preferentially inhibit the in vitro
catalytic activity of human CYP1B1.
4.1.2.4. Elimination
No data available.
4.1.2.5. Pharmacokinetic interactions with other medicinal products
Studies with defined Ginkgo biloba extract (EGb 761)
Robertson et al. (2008): Evaluation of an open-label study in 14 healthy volunteers showed that
lopinavir, ritonavir and fexofenadine (probe drug for P-gp) exposures were not significantly affected by
Ginkgo biloba (according to an internet research the used extract is probably EGb 761) administration
of 120 mg twice daily for 2 weeks. However, Ginkgo biloba decreased midazolam (probe drug for
CYP3A4) AUC 0- and C max by 34% (p=0.03) and 31% (p=0.03), respectively, relative to baseline.
Uchida et al. (2006): This study was performed to demonstrate the influence of repeated oral
administration of EGb 761 (120 mg three times daily for 28 days) on CYP2C9 and CYP3A4. CYP2C9
probe (tolbutamide, 125 mg) and CYP3A4 probe (midazolam, 8 mg) were orally administered to 10
male healthy volunteers (mean age SD: 24.9 2.6 years) before and after EGb 761 intake, and
they received 75 g glucose after tolbutamide administration. AUC 0- for tolbutamide after EGb 761
intake was slightly but significantly (16%) lower than that before EGb 761 intake. Concomitantly,
EGb 761 tended to attenuate AUC 0-2 of blood glucose-lowering effect of tolbutamide. AUC 0- for
midazolam was significantly (25%) increased by EGb 761 intake and oral clearance was significantly
(26%) decreased.
Markowitz et al. (2003) assessed in normal volunteers (n=12) aged 22-40 years the influence of
EGb 761 on the activity of CYP2D6 and 3A4 normal volunteers phenotyped as CYP2D6 extensive
metabolisers. Probe substrates dextromethorphan (CYP2D6 activity) and alprazolam (CYP3A4 activity)
were coadministered orally at baseline, and following treatment with EGb 761(120 mg twice daily) for
14 days. Urinary concentrations of dextromethorphan and dextrorphan were quantified and
dextromethorphan metabolic ratios (DMRs) were determined at baseline and after EGb 761 treatment.
Likewise, plasma samples were collected (0-60 hours) for alprazolam pharmacokinetics at baseline and
after EGb 761 treatment to assess effects on CYP3A4 activity. Validated HPLC methods were used to
quantify all compounds and relevant metabolites. No statistically significant differences were found
between baseline and post-EGb 761 treatment DMRs indicating a lack of effect on CYP2D6. For
alprazolam there was a 17% decrease in the area under the plasma concentration versus time curve
(AUC); (p<0.05). However, the half-life of elimination was not significantly different after EGb 761
administration indicating a lack of hepatic CYP3A4 induction. The usual interpretation of altered C max
and no variation in the half-life of elimination is that absorption rather than hepatic enzyme activity
has been affected.
Page 53/120
Greenblatt et al. (2006): The study shows that short-term exposure to EGb 761 in a dosage of
360 mg per day does not influence the kinetics of CYP2C9 activity. 11 healthy volunteers received
single 100 mg doses of flurbiprofen, a probe substrate for CYP2C9, and EGb 761 or placebo in a
randomised, double-blind, 2-way crossover study. None of the mean kinetic variables differences for
flurbiprofen with either placebo or EGb 761 were significant. Based on HPLC analysis, each 60 mg
ginkgo tablet contained 6.6 g of amentoflavone and 61.2 g of quercetin, both previously identified as
CYP2C9 inhibitors. These amounts were apparently too low to inhibit CYP2C9 function in vivo. These
results confirm previous controlled clinical studies showing no effect of ginkgo on the kinetics of
warfarin, which is known as a substrate of CYP2C.
Zadoyan et al. (2011): The objective of this open-label, single-center, randomised, threefold crossover study was to assess the in vivo herbal drug-drug interaction potential of EGb 761 with respect to
the activities of the five major human drug-metabolising cytochrome P450 (CYP) enzymes. 18 healthy
volunteers received in random order placebo twice daily, EGb 761 120 mg twice daily, and EGb 761
240 mg in the morning and placebo in the evening for 8 days. After the mentioned pretreatment, on
day 8, administration was performed together with the orally administered phenotyping cocktail:
150 mg caffeine, 125 mg of tolbutamide, 20 mg omeprazole, 30 mg dextromethorphan, and 2 mg of
midazolam. No relevant pharmacokinetic interaction was assumed if the 90% CIs for EGb 761/placebo
ratios of pharmacokinetic parameters were within the 0.70-1.43 range. The results show respective CIs
were within the specified margins for all ratios except CYP2C19 for EGb 761 120 mg twice daily (90%
CI 0.681-1.122) and for CYP2D6 for EGb 761 240 mg once daily (90% CI 0.667-1.281). These findings
were attributed to the intraindividual variability of the metrics used. In conclusion, EGb 761 has no
relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no
relevant potential to cause respective metabolic drug-drug interactions.
Blonk et al. (2012) studied the effect of EGb 761 on the pharmacokinetics of raltegravir in an openlable, randomised, two-period, crossover phase I trial in 18 healthy volunteers between the ages of 18
and 55 years. Subjects received 120 mg EGb 761 twice daily for 15 days plus a single dose of
raltegravir (400 mg) on day 15, a washout period, and 400 mg of raltegravir on day 36 or the test and
reference treatments in reverse order. Pharmacokinetic sampling of raltegravir was performed up to
12 hours after intake on an empty stomach. All subjects completed the trial, and no serious adverse
events were reported. Steady-state EGb 761 increased the mean exposure to raltegravir (AUC 0- ) by
21% and the C max by 44%. The apparent elimination half-life of raltegravir did not appear to be
influenced by EGb 761. Geometric mean ratios (90% CI) of the area under the plasma concentrationtime curve from dosing to infinity (AUC 0- ) and the maximum plasma concentration (C max ) of
raltegravir with EGb 761 versus raltegravir alone were 1.21 (0.93 to 1.58) and 1.44 (1.03 to 2.02).
Besides EGb 761 did not reduce raltegravir exposure, the observed increase in C max may be caused by
a change in absorption than by inhibition of the metabolim of raltegravir, because the elimination halflife of raltegravir remained unaffected. At which the increase in C max is not considered to be of clinical
importance. A possible explanation for the increase in the C max and bioavailability of raltegravir when
combined with EGb 761 could be the inhibition of P-gp by EGb 761. Although in vitro characterisation
of raltegravir transport by drug transporters indicates that raltegravir is a weak P-gp substrate, one
must be cautious because it is not yet confirmed in human studies.
In the article by Zagermann-Muncke (2006) the role of transport proteins in view of
pharmacokinetic interactions is discussed. The ABC transporter P-gp can be both inhibited and induced,
whereas P-gp substrates are usual substrates of CYP3A4 as well. Expression and activity of both
proteins are apparently regulated in part through the same menchanisms. Thereby differentiation of
effects is hindered. A list of P-gp substrates, inducers and inhibitors is given. The concomitant intake of
a P-gp substrate and a P-gp inhibitor is possibly leading to a higher bioavailability of the P-gp
substrate. This could be clinically relevant for drugs with narrow therapeutic index. Genetically based
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 54/120
MDR-1 (gene that encodes for P-gp) polymorphism can change transport function and expression of Pgp, therefore efficacy and tolerance of drugs, which are P-gp substrates, can vary between humans.
Jiang et al. (2005) analysed the effect of EGb 761 (80 mg three times daily) on pharmacokinetics of
warfarin in an open-label, three-way, crossover and randomised study. 12 healthy male subjects
received a single 25 mg dose of warfarin alone or after 7 days pre-treatment with EGb 761. Dosing
with Ginkgo biloba extract was continued for 7 days after warfarin administration. There was no
relevant influence on the apparent clearance of S- and R-warfarin. EGb 761 did not affect the apparent
volumes of distribution or protein binding of either S-warfarin or R-warfarin. Therefore, EGb 761 at
recommended doses does not significantly affect the pharmacokinetics of warfarin in healthy subjects.
Lu et al. (2006): To examine whether ticlopidine coadministration with EGb 761 would affect
pharmacokinetics of ticlopidine 8 healthy volunteers were included in a sequential 3-phase study.
Subjects were treated with a single oral dose of 250 mg ticlopidine alone or after pretreatment with
EGb 761 (40 mg 3 times daily) for 4 days. Ticlopidine and EGb 761 significantly inhibited the organic
anion transporting polypeptide (OATP-B)-mediated uptake of [H]-estrone-3-sulfate in a
concentration-dependent manner. When EGb 761 is coadministered with ticlopidine there were no
changes in the pharmacokinetic parameters of ticlopidine.
Kudolo et al. (2006): A study is described which was designed as a double-blind, placebo-controlled,
crossover trial to determine if the coingestion of EGb 761 and metformin would alter the
pharmacokinetic properties of metformin in type 2 diabetic patients and in non-diabetic persons. The
participants ingested either EGb 761 (120 mg/day as a single dose) or placebo for 3 months. At the
end of the period the non-diabetic persons took a single 500 mg dose of metformin and the diabetic
subjects took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761.The
pharmacokinetic parameters of metformin (500 mg) were all significantly different (p<0.05) between
the normal glucose tolerance and 8 out of 10 diabetic subjects who received metformin during the
placebo cycles. During the EGb 761 cycles, only the elimination half-life in the type 2 diabetic patients
was significantly increased. In conclusion, coingestion of 120 mg EGb 761 and 500 mg metformin did
not significantly affect the pharmacokinetic properties of metformin.
Gardner et al. (2007): The purpose of this randomised, double-blind, placebo-controlled, parallel
clinical trial was to determine potential adverse effects of concomitant intake of aspirin and EGb 761 on
platelet function. EGb 761 (300 mg/day) was compared with placebo for effects on measures of
platelet aggregation among adults (6910 years) consuming 325 mg/day aspirin. Participants were
afflicted with peripheral artery disease (PAD) or had risk factors for cardiovascular disease. Outcome
measures included platelet function analysis (PAF-100 analyser) using ADP as agonist, and platelet
aggregation using ADP, epinephrine, collagen and ristocetin as agonists. There were no clinically or
statistically significant differences between treatment groups for any agonists, for either PAF-100
analysis or platelet aggregation. In conclusion, in older adults with PAD or cardiovascular disease risk,
a relatively high dose of EGb 761 combined with 325 mg/day daily aspirin did not have a clinically or
statistically detectable impact on indices of coagulation examined over 4 weeks, compared with the
effect of aspirin alone. No adverse bleeding events were observed.
Studies with other Ginkgo biloba extracts
Bressler (2005) presented in a review article known drug interactions with Ginkgo biloba (not
further specified). In a table interactions with the following prescription drugs are listed: alprazolam,
haloperidol, trazodone, omeprazole, aspirin, ibuprofen, nifedipine and warfarin. To specify these
interactions, systemic exposure to alprazolam may be slightly decreased by Ginkgo biloba. Ginkgo
biloba can increase the effectiveness and decrease the extrapyramidal side effects of haloperidol and
can increase the risk of sedation when taken together with trazodone. Plasma concentrations of
Page 55/120
omeprazole may be reduced when the medicinal product is taken together with Ginkgo biloba which
can result in decreased efficacy of the drug. Administration of Nifedipine and Ginkgo biloba at once
may elevate plasma concentrations of the cardiovascular agent. Based on the suspected mechanism of
action that Ginkgo biloba can also inhibit CYP3A4, it may causes increased levels of drug, prolonged
drug effects, and increased drug toxicity. The risk of bleeding may be increased when Ginkgo biloba is
administered concomitantly with aspirin, ibuprofen or warfarin.
Mahadevan and Park (2008) mentioned with references to the primary literature interactions of
Ginkgo biloba extract with the following substances: antidepressants (i.e. trazodone), antiepileptics,
antidiabetics, diuretics, and nonsteroidal anti-inflammatory drugs, as well as other herbal drugs. These
interactions are believed to be affected mainly by flavonol glycosides and the terpene lactones by
selectively inhibiting particular enzymes, including cytochrome P450. However, others reported no
effect on clearance of cytochrome P450 substrates by ginkgo leaf extract.
Yoshioka et al. (2004b): The effects of Ginkgo biloba leaf extract (manufactured in Chiba, Japan) on
the pharmacokinetics of nifedipine (NFP), a calcium-channel blocker, were studied using 8 healthy
volunteers. Concomitant oral administration of Ginkgo biloba (240 mg) did not significantly affect any
of the mean pharmacokinetic parameters of either NFP or dehydronifedipine, a major metabolite of NFP
after oral intake of 10 mg NFP. Still, the C max of NFP in 2 subjects was approximately doubled by GBE,
and they had severer and longer-lasting headaches with Ginkgo biloba than without Ginkgo biloba,
with dizziness or hot flushes in combination with Ginkgo biloba extract. In addition the mean heart rate
after oral administration of NFP with ginkgo extract tended to be faster than that without Ginkgo biloba
extract at every time point. In conclusion, Ginkgo biloba extract and NFP should not be simultaneously
ingested as much as possible and careful monitoring is needed when administering NFP concomitantly
with Ginkgo biloba to humans.
Fan et al. (2009a): The aim of the present study was to assess the effects of Ginkgo biloba extract
(not further specified) on the pharmacokinetics of talinolol, a P-glycoprotein substrate. 12 healthy male
volunteers took a single 100 mg oral dose of talinolol either alone (control group) or after pretreatment with 120 mg Ginkgo biloba extract three times daily for 14 days. Ginkgo biloba extract
treatment considerably increased talinolol AUC 0-24 and C max by 21% (p=0.002) and 33% (p=0.002),
respectively, whereas t and t max indicated no alteration. The results suggest that Ginkgo biloba
extract significantly inhibited P-glycoprotein in humans.
Fan et al. (2009b) investigated the effects of single and repeated Ginkgo biloba extract ingestion on
the oral pharmacokinetics of talinolol. Ten healthy male volunteers participated in a 3-stage sequential
study. Plasma concentrations of talinolol were measured by HPLC after talinolol 100 mg was
administered alone, with a single oral dose of Ginkgo biloba extract (120 mg), and after 14 days of
repeated Ginkgo biloba extract ingestion (360 mg/day). A single oral dose of GBE did not affect the
pharmacokinetics of talinolol. Repeated ingestion of Ginkgo biloba extract significantly increased C max
(36%), AUC 0-24 (26%) and AUC 0- (22%) of talinolol without significant changes in elimination half-life
and the time to C max . These results indicate that long-term use of Ginkgo biloba extract significantly
influence talinolol disposition in humans, likely by affecting the activity of P-glycoprotein inhibition
and/or other drug transporters.
Yin et al. (2004) designed this study to investigate the potential herb-drug interaction between
Ginkgo biloba leaf extract (containing 22.9% flavonol glycosides and 6.8% terpene lactones) and
omeprazole, a widely used CYP2C19 substrate. 18 healthy Chinese subjects with different CYP2C19
genotypes received a single omeprazole 40 mg at baseline and then at the end of a 12-day treatment
period with Ginkgo biloba leaf extract (140 mg, 2 times daily). The resulting pharmacokinetic
parameters of omeprazole, and its metabolites, 5-hydroxyomeprazole and omrprazole sulfone, show
that Ginkgo biloba leaf extract can induce omeprazole hydroxylation in a CYP2C19 genotype-dependent
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 56/120
Page 57/120
Mohutsky et al. (2006) conducted two open-label, crossover pharmacokinetic studies in healthy
volunteers to determine the effect of Ginkgo biloba extract (Ginkgold, Natures Way, Springville, UT)
on 2 probe substrates of CYP2C9, diclofenac and tolbutamide. Diclofenac study: Diclofenac potassium
50 mg (immediate release) was administered to 12 subjects twice daily for 14 days. Gingko biloba
extract tablets, 120 mg twice daily, were given concurrently on days 8-15. Tolbutamide study:
Tolbutamide was administered as single 500 mg oral dose to 6 subjects. After a minimum of a 2-week
washout period, the subjects started Ginkgo biloba treatment phase consisting of 120 mg Ginkgo
biloba extract twice daily for 3 days. On day 4, the patients received a second 500 mg dose of
tolbutamide. No interactions between Ginkgo biloba extract and CYP2C9 probe substrates were
observed in vivo as evidenced by the lack of effect on the steady-state pharmacokinetics of diclofenac
or on the urinary metabolic ratio of tolbutamide.
Gurley et al. (2005) noted no effect of Ginkgo biloba on cytochrome P450 activity in this open-label
study. The aim of this study was to determine whether long-term supplementation, beside others, of
Ginkgo biloba (60 mg four times daily standardised to 24% flavone glycosides and 6% terpene
lactones) affected cytochrome P450 activity. 12 healthy volunteers (60-76 years) were randomly
assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe
drug cocktails of 8 mg midazolam, 100 mg caffeine, 500 mg chlorzoxazone and 5 mg debrisoquine
were administered before and at the end of supplementation. Pre- and post-supplementation
phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6. Comparisons of preand post-Ginkgo biloba phenotypic ratios revealed no significant changes in the CYP activity tested in
this study.
Yasui-Furukori et al. (2004) designed the study to examine the effect of Ginkgo biloba extract
(manufactured in Ichoha Sainoshin, Aihoupu Co., Kagoshima, Japan) on the pharmacokinetics of
donepezil in 14 elderly patients with Alzheimers disease. Subjects received donepezil 5 mg/day,
supplemented with Ginkgo biloba extract 90 mg/day for 30 days. Plasma drug concentration was
measured using HPLC. The resulting plasma concentration of donepezil during GBE supplementation
(meanSD [95% CI]; 24.412.6 ng/ml [17.1-31.7 ng/ml]) was not significantly different from that
before ginkgo supplementation (22.710.3 ng/ml [16.8-28.7 ng/ml]) or that 4 weeks after its
discontinuation (25.012.9 ng/ml [17.6-32.4 ng/ml]). In conclusion, the results show that ginkgo
supplementation does not have major impact on the pharmacokinetics of donepezil.
Page 58/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
Herrschaft et
24 weeks
EGb 761
n=410
mild to moderate AD
improvement of
119 AE in 91 (44.4%)
al. 2012
randomised,
(240 mg
n=205
or VaD associated
double-
once daily)
verum
with neuropsychiatric
blind,
or placebo
n=205
symptoms
placebo-
placebo
controlled
50
score improved by
no major differences,
years
both drug-placebo
comparisons were
significant at p<0.001
Ihl et al.
2010a
24 weeks
EGb 761
n=404
Mild to moderate
improvement of SKT
no difference of
randomised,
(240 mg
n=202
dementia with
total score
incidence of AE in the
double-
once daily)
verum
neuropsychiatric
(cognitive efficacy)
treatment groups;
blind,
or placebo
n=202
features, at least 50
placebo-
placebo
years, probable AD in
total score
group, improvement of
controlled,
50
(neuropsychiatric
parallel
years
NINCDS-ADRA
dizziness: 19 (9.2%) in
criteria, possible AD
period
with cerebrovascular
placebo group,
(11.3%) in placebo
disease (CVD) as
significant superiority of
Page 59/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
defined by the
NINDS-AIREN criteria
in both primary
or probable VaD
endpoints (p<0.001)
age
according to NINDS-
placebo group
AIREN, symptoms of
rapid deteriora-tion of
6 months, CT or MRI
function)
22 weeks
EGb 761
n=391
mild to moderate
mean -3.2-point
and
randomised,
(120 mg
n=196
dementia with
improvement in the
Borzenko
double-
twice daily)
verum
neuropsychiatric
2007
blind,
or placebo
n=195
features; 50 years,
average deterioration
placebo-
placebo
probable AD
by +1.3 points on
controlled,
50
(NINCDS-ADRDA),
placebo (p<0.001);
parallel
years
possible AD
36 (18%) in placebo
(NINCDS/ADRDA),
significantly superior to
group; 7 non-fatal
serious AE were
SKT
Page 60/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
(NINDS-AIREN), CT or
secondary)efficacy
and 13 on placebo; no
variables (p<0.001)
event of bleeding
age
22 weeks
EGb 761
n=96
AD and
no primary outcome
improvement in all
randomised,
(120 mg
n=30
neuropsychiatric
measures were
group, 73% in
double-
twice daily),
verum
features, meet
defined, outcome of
in all groups, no
blind,
or donepizil
n=29
NINCDS/ADRAD
statistically significant
56% in combined
donepezil-
(5 mg once
control
differences, relatively
controlled,
daily during
n=29
36 on the TE4D,
AE (related to study
parallel
first 4
verum
Test (cognitive
significant, slight
weeks,
+control
superiority of the
Page 61/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
10 mg
50
between 9 and 23 on
combined treatment
during last
years
(behavioural and
frequent: headache,
18 weeks),
psychological
insomnia, diarrhoea,
or combined
item NPI
and fatigue
treatment
(overall geriatric
(at recom-
assessment)
mended
doses)
Kanowski et
al. 1996
24 weeks
EGb 761
n=156
mild to moderate
psychopathological
122 AE, 63 AE on
randomised,
(120 mg
n=79
primary degenerative
assessment (CGI),
double-
twice daily)
verum
dementia of the AH
cognitive
placebo; gastro-
blind,
or placebo
n=77
type or multi-infarct
performance
placebo (p<0.05), in
intestinal disorders
placebo
placebo
assessment (SKT),
occurred more
controlled,
55
assessment of
parallel
years
(inclusive), MMSE
behaviour (NAB),
frequency of therapy
intensity on placebo; 7
clinical efficacy
responders differed
serious AE (5 on
(inclusive)
assessment (therapy
significantly in favour of
response defined as
response in at least
AE suspected acute
primary variables-
(investigator declined
to comment)
Page 62/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
Heinen-
12 months
n=683
mild to moderate
quality of life of
according to PLC a
14 inpatient stays (5 on
Kammerer et
non-
dose
n=281
dementia;
care-taking relatives
significant improvement
EGb 761, 9 on
al. 2005
randomised,
mentioned)
verum
in quality-of-life of care
standard) causally
two-armed,
or standard
n=402
taking relatives
determined to dementia
open,
(no Ginkgo
standard
of life profile of
standard-
biloba
chronically ill
(positive mood
controlled,
extract,
65-80
as caregiver at home,
speak German, no
patients)
p=0.018, negative
parallel
previous
years
standard
aphasia, signed
informed consent
therapy
group
could be
continued)
Le Bars et
al. 1997
52 weeks
EGb 761
n=309
mildly to severely
changes in cognitive
randomised,
(40 mg three
n=155
demented patients
impairment (ADAS-
to the study
double-
times daily)
verum
with AD or multi-
blind,
or placebo
n=154
infarct dementia,
group; no significant
placebo
placebo
without other
(GERRI), and in
controlled,
45
significant medical
general
to moderate intensity
parallel
years
conditions
psychopathology
a significant worsening
(167/188); AE of
(CGIC)
on placebo; mild
improvement in the
placebo) resulted in
withdrawal in 2 patients
significant worsening on
Page 63/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
placebo;
p=0.02), statistically
gastrointestinal events
significant difference in
(18 of 29 events)
age
(p=0.004); slight
worsening for both
treatment groups on
the CGIC; AD subgroup
analysis: similar results
for both treatments,
differences were
significant on ADASCog (p=0.02) and
GERRI (p<0.001)
Hofferberth
1989
8 weeks
EGb 761
n=36
cerebro-organic
quantitative EEG,
highly significant
randomised,
(40 mg three
n=18
Syndrome;
saccadic test,
positive attitude in
double-
times daily)
verum
Haschinsky-Score,
Wiener
also 8 weeks in
verum group; 3 AE in
blind,
or placebo
n=18
EEG-theta ratio of
Determination Test,
placebo-
placebo
ZVT
psychometric tests
controlled
53-69
spectrum, saccadic
(Wiener Determination
out
years
saccadic speed of
placebo, saccade
250/s, saccade
Page 64/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
duration more than
number of correct
Determination Test
answers in Wiener
ZVT increased
significantly on
(more than 28
reduction in theta
seconds for
proportion of the
Halama et
12 weeks
EGb 761
n=40
mild to medium
SCAG score,
no drop out; 1 AE in
al. 1988
randomised,
(40 mg three
n=20
cerebrovascular
descriptive: HIV
dropped on average by
double-
times daily)
verum
insufficiency;
(Hintergrundinterfer
moderate headache)
blind,
or placebo
n=20
enz-Verfahren),
and remained
placebo-
placebo
SKT, CCG
unchanged on placebo
controlled
55-85
3 (score 11-21)
(Craniocorpographie
(difference between
), symptom-rating
treatment groups
years
p=0.00005), an effect
in SCAG-items
particularly on
disturbances of short-
Page 65/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
term memory and
mental awareness,
specific verum effect on
the SKT, no effect
shown on HIV and CCG,
superior effects were
also shown in the
symptoms of dizziness,
headaches and tinnitus
Eckmann
6 weeks
Ginkgo
n=58
cerebral insufficiency
changes in 12
1990
randomised,
biloba
n=29
typical symptoms
improvements on
double-
extract
verum
symptom depressive
after 2, 4 and 6
blind,
(solution
n=29
mood
weeks
of improvements
placebo-
Kaveri,
placebo
significantly larger on
controlled
three times
41-71
daily, daily
years
weeks differences in
dosage
160 mg or
rather 40 mg
6 weeks differences in
ginkgoflavon
11 of the 12 symptoms,
glycosides)
largest number of
or placebo
improvements on
not indicated
Page 66/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
Mazza et al.
24 weeks
Ginkgo
n=76
mild to moderate
no significant change
2006
randomised,
biloba
n=25
dementia;
MMSE
double-
special
ginkgo
blind,
extract E.S.
n=25
donepezil due to AE
placebo-and
(Flavogin,
donepezil
Rating Scale,
donepezil
160 mg
n=26
Hachinski Ischemic
controlled
daily-no
placebo
treatment compared
further
50-80
(global assessment),
details) or
years
donepezil
(5 mg daily-
between 13 and 25
no further
(inclusive)
details) or
placebo
Schneider et
al. 2005
26 weeks
EGb 761
n=513
mild to moderate
ADAS-cog, ADCS-
no differences between
Dizziness cases:
CGIC
cognitive endpoint,
randomised,
(60 mg or
n=169
dementia of the
double-
120 mg
verum
Alzheimer type
blind,
twice daily)
(120 mg)
240 mg group 11
placebo-
or placebo
n=170
differ significantly
controlled,
verum
among treatment
group 12 (6.9%); in 4
parallel
(240 mg)
groups
out of 42 serious AE a
n=174
placebo
considered unlikely
60
Page 67/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
years
Van Dongen
24 weeks
n=214
dementia (either AD
NAI-ZVT-G, NAI-ZN-
et al. 2000
randomised,
or 120 mg
n=84
or VaD; mild to
G, NAI-WL, SCAG,
double-
twice daily)
verum
moderate degree) or
GDS, self-perceived
patients on ginkgo
blind,
or placebo
(160 mg)
age-associated
compared to placebo
placebo-
n=82
memory impairment
status, and
placebo groups,
controlled,
verum
behavioural
respectively; most
parallel,
(240 mg)
assessment
common: dizziness
after 12
n=48
(n=58), nervousness
weeks
placebo
(n=49), headache
ginkgo users
50
were
randomised
years
once again
to continued
ginkgo or
possible association
Page 68/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
McCarney et
al. 2008
placebo
treatment
placebo user)
6 months
EGb 761
n=176
mild to moderate
cognitive functioning
no significant effect
total of 63 AE, 29
randomised,
(60 mg twice
n=88
dementia; 55 years,
(ADAS-Cog),
between treatment
double-
daily) or
verum
presence of a carer,
participant and
blind,
placebo
endpoint
fatal cerebral
n=88
informed consent,
carer-rated quality
placebo-
placebo
sufficient command of
of life (QOL-AD)
controlled,
55
English, clinical
parallel
years
diagnosis of dementia,
haemorrhage in ginkgo
group
12 weeks
EGb 761
n=300
efficacy and
most frequently
Kapanke et
randomised,
(240 mg
al. 2011
double-
once daily)
n=150
impairment (vMCI),
tolerability of
cognitive functioning
gastrointestinal
verum
subjective complaints
symptoms and
blind,
or placebo
n=150
of impairment, low
(measure of
of life
infections and
placebo-
control
functioning in at least
attention and of
infestations; no serious
controlled,
45-65
memory, perceived
AE
parallel
years
tests, perceived
physical health)
impairment for at
least 3 months, total
score above 23 in the
Page 69/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
MMSE, intact activities
of daily living, no
indication of dementia
DeKosky et
6.1 years
EGb 761
n=3069
normal cognition or
diagnosis of
no statistically
al. 2008
randomised,
(120 mg
n=1545
MCI, 75 years
dementia by DSM-IV
significant differences
double-
twice daily)
verum
criteria
blind,
or placebo
n=1524
placebo-
placebo
controlled,
75
treatment groups
parallel
years
Burle et al.
6 weeks
Ginkgo
n=59
DemTect (mental
no significant change in
2009
open
biloba fresh
>60
plant extract
years
performance), SF-12
gastrointestinal
no obvious symptoms
(quality of life), 5-
disturbances and 18 AE
(90 mg twice
of dementia in the
12 mental subscore
were evaluated as
daily)
judgement of the
in symptoms), 4-
increased significantly
investigator, signed
point scale
by 3 points to 51.57.9
medication, transient
informed consent, at
(assessing efficacy
(p=0.013), symptoms
improved in 41.3%
following symptoms:
the investigator),
(forgetfulness), 43.1%
forgetfulness,
questioning of
(impaired
impaired
retreatment
concentration), and
concentration, or
(acceptance of
34.5% (impaired
the tolerability
impaired memory,
treatment)
Page 70/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
medication for
patients assessed
improvement of
efficacy as good or
mental performance
noticed no effect,
investigators rated
tablets as effective or
study
Vellas et al.
2012
5 years
EGb 761
n=2854
spontaneously
conversion to
61 participants (1.2
probable AD
randomised,
(120 mg
n=1406
reported memory
incidence of other
double-
twice daily)
verum
complaints to
haemorrhagic or
blind,
or placebo
n=1414
primary-care
placebo-
placebo
physician
controlled,
70
person-years) in the
parallel
years
Page 71/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
Brautigam et
24 weeks
Geriaforce,
n=241
Memory and/or
in subjective test,
al. 1998
randomised,
fresh plant
n=77
concentration
effects were
double-
extract
high dose
complaints
no significant
gastrointestinal
blind,
(ethanol
n=82 low
2, subjective
differences in
complaints; no
placebo-
70% V/V,
dose
perception of
improvement between
differences in the
controlled
DER 1:4,
n=82
memory and
total flavone
placebo
concentration
glycosides
55-86
0.2 mg/ml,
years
dizziness: HD group 3,
respectively
total
ginkgolides
0.34 mg/ml),
high dose
group, 1 in LD group
(HD): 40
and 3 on placebo
drops ginkgo
extract three
times daily,
low dose
(LD): 40
drops ginkgo
extract 1:1
with placebo
three times
daily or
placebo
Page 72/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
Kaschel
6 weeks
EGb 761
n=188
mentally healthy,
assess effects on
significant improvement
2011
randomised,
(240 mg
n=94
long-term memory,
not significantly
double-
once daily)
verum
level secondary
replicate evidence
of recall of
different between
blind,
or placebo
n=94
suggesting that
appointments, no
treatment groups
placebo-
placebo
middle or high
objective
superiority of ginkgo in
controlled,
45-65
school), sufficient
improvement is
another everyday
parallel
years
language skills to
paralleled by
memory test
understand and
changes in
(recognition of a driving
respond to interview
subjective memory
route)
questions and
undergo
in objective
neuropsychological
psychometric test
testing without
performance with
everyday life in
terms of ecological
provided written
validity
informed consent
Dodge et al.
42 months
Ginkgo
n=118
normal elderly, 85
mild cognitive
14 cases among
2008
randomised,
biloba
n=60
years, informant
decline (defined as
double-
extract
verum
available, no
blind,
(GBE, at
n=58
subjective memory
decline in memory
progressed to
were non-haemorrhagic
placebo-
least 6%
placebo
complaint, normal
controlled
terpene
85
memory function,
showed a tendency of
lactones and
years
adverse events
Page 73/120
Study
Treatment
Study and
Number
Diagnosis, inclusion
criteria
duration
control
of
Study
drugs, daily
subjects
design
dose
by arms,
Primary endpoints
Efficacy results
Safety results
age
24% flavone
function, no difference
glycosides)
in adverse events
80 mg three
(p=0.44)
times daily
or placebo
The following table summarises relevant data from the table above concerning the age associated meaning of dementia. Most studies are conducted with
patients aged 50 and older. Four studies included patients with a minimum age of 41 (one study) or rather 45 (three studies). No data are given about the
number of patients with corresponding age. To compare the mean age the lowest mean age of the older age studies is 63 years. In comparison to the
studies with patients aged 41 or rather 45 the mean age is in the range of 54-56, except one study by Le Bars et al (1997). In this trial the mean age (69
years) is in the range of the mean age of studies with older aged patients. The three studies, which show no comparable mean age to the rest of the studies,
include a low number of patients or a diagnosis which has no relevance in supporting the monograpf relevant indication.
Study
Patients (No.)
Age
Diagnosis
Efficacy results
n=410
50 years
Mild to moderate AD or
neuropsychiatric
symptoms
n=404
50 years
with neuropsychiatric
features
Page 74/120
Study
Patients (No.)
Age
Diagnosis
Efficacy results
EGb 761 group and 24% in placebo group, significant
superiority of EGb 761 over placebo in both primary
endpoints (p<0.001)
Napryeyenko and
n=391
Borzenko 2007
50 years
with neuropsychiatric
features
years
n=96
n=156
50 years
AD and neuropsychiatric
features
drugs
55 years
degenerative dementia of
70 years
Heinen-Kammerer et
n=683
al. 2005
n=309
65-80 years
years
45 years
Mildly to severely
years
or multi-infarct dementia
Page 75/120
Study
Patients (No.)
Age
Diagnosis
Efficacy results
worsening on placebo (0.08 points; p=0.02),
statistically significant difference in favour of
EGb 761 (p=0.004); slight worsening for both
treatment groups on the CGIC; AD subgroup
analysis: similar results for both treatments,
differences were significant on ADAS-Cog (p=0.02)
and GERRI (p<0.001)
Hofferberth 1989
n=36
53-69 years
Cerebro-organic Syndrome
years
n=40
55-85 years
Mild to medium
cerebrovascular
insufficiency
years
Eckmann 1990
n=58
41-71 years
depressive mood
years
Page 76/120
Study
Patients (No.)
Age
Diagnosis
Efficacy results
differences in 11 of the 12 symptoms, largest
number of improvements on ginkgo between week 2
and 4 (2/3 of patients)
n=76
50-80 years
placebo (p=0.01)
years
Schneider et al. 2005
n=513
60 years
n=214
2000
50 years
Dementia (either AD or
years
degree) or age-associated
memory impairment
n=176
55 years
n=300
2011
DeKosky et al. 2008
n=3069
45-65 years
impairment (vMCI)
of quality of life
75 years
n=59
>60 years
Mean age: 72 years
Page 77/120
Study
Patients (No.)
Age
Diagnosis
Efficacy results
significantly by 3 points to 51.57.9 (p=0.013),
symptoms improved in 41.3% (forgetfulness), 43.1%
(impaired concentration), and 34.5% (impaired
memory), 61% of the patients assessed efficacy as
good or rather good, 28.8% noticed no effect,
investigators rated tablets as effective or very
effective in 69.4%, and as not effective in 23.7%,
90% would take the tablets again
n=2854
70 years
Spontaneously reported
memory complaints to
years
primary-care physician
n=241
55-86 years
Memory and/or
concentration complaints
69 years
Kaschel 2011
n=188
n=118
45-65 years
Mentally healthy
ears
driving route)
85 years
Mean age is not given
Normal elderly
Page 78/120
Study
Indication
Treatment duration
24 weeks
Test product
EGb 761
Single/Daily dosage
240 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
n=17
number of patients
age
50 years
wash-out
4 weeks
Page 79/120
Outcome
Patients treated with EGb 761 improved by 2.23.5 points (mean sd) on
the SKT total score, whereas those receiving placebo changed only slightly
by 0.33.7 points. The NPI composite score improved by 4.67.1 in the
EGb 761-treated group and by 2.16.5 in the placebo group. Both drugplacebo comparisons were significant at p<0.001. Patients in the EGb 761
group also showed a more favourable course in most of the secondary
efficacy variables (ability to cope with the demands of everyday living,
quality of life and clinicians global judgement).
Authors conclusion: Treatment with EGb 761 at a once daily dose of
240 mg was safe and resulted in a significant and clinically relevant
improvement in cognition, psychopathology, functional measures and
quality of life of patients and caregivers.
Study
Indication
Treatment duration
24 weeks
Test product
EGb 761
Single/Daily dosage
240 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=20
number of patients
age
50 years
wash-out
up to 4 weeks
Outcome
Patients treated with EGb 761 improved by -1.4 (95% CI -1.8; -1.0) points
on the SKT and by -3.2 (-4.0; -2.3) on the NPI total score, whereas those
receiving placebo deteriorated by +0.3 (-0.1; 0.7) on the SKT and did not
change on the NPI total score (-0.9; 0.9). Both drug-placebo comparisons
were significant at p<0.001. EGb 761 was significantly superior to placebo
with respect to Alzheimers Disease Cooperative Study Clinical Global
Impression of Change (ADCS-CGIC), Activities of Daily Living International
Scale (ADL-IS), NPI distress score, DEMQOL-Proxy quality-of-life scale and
Verbal Fluency Test. Averse event rates were similar for both treatment
groups.
Page 80/120
Authors conclusion: EGb 761, 240 mg once daily, was found significantly
superior to placebo in the treatment of patients with dementia with
neuropsychiatric symptoms.
Study
Outcome
Correlations between changes from baseline and NPI baseline scores were
weak to modest, but conspicuously different between active drug and
placebo groups. The slopes of the regression lines for the EGb 761 and the
placebo groups showed qualitative and statistically significant differences:
With increasing NPI baseline scores there was faster deterioration in the
placebo group and thus more net benefit from treatment for the EGb 761
group. EGb 761 was effective in the treatment of dementia irrespective of
the severity of neuropsychiatric symptoms.
Study
Outcome
EGb 761 treatment was superior to placebo with respect to the SKT total
score (drug-placebo differences: 1.7 for AD, p<0.001, and 1.4 for VaD,
p<0.05) and the NPI total score (drug-placebo differences: 3.1 for AD,
p<0.001 and 3.2 for VaD, p<0.05). Significant drug-placebo differences
were found for most secondary outcome variables (ADCS-CGIC, ADL-IS,
the DEMQOL-proxy quality of life scale, and the Verbal Fluency Test) with
no major differences between AD and VaD subgroups. Rates of adverse
effects were essentially similar in both groups.
Authors conclusion: EGb 761 improved cognitive functioning,
neuropsychiatric symptoms and functional abilities in both types of
dementia.
Study
Outcome
Primary outcome: NPI composite score improved by -3.2 (95% CI -4.0 to 2.3) in patients taking EGb 761, no change (-0.9; 0.9) in those receiving
placebo
Secondary outcome: NPI distress score (evaluate caregivers distress)
revealed similar baseline pattern and improvements
Authors conclusion: Treatment with EGb 761, at once-daily dose of
240 mg, was safe, effectively alleviated behavioural and neuropsychiatric
symptoms in patients with mild to moderate dementia, and improved the
wellbeing of their caregivers.
Page 81/120
Study
Indication
Treatment duration
22 weeks
Test product
EGb 761
Single/Daily dosage
120 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=16
number of patients
Outcome
age
50 years
wash-out
up to 4 weeks
There was a mean -3.2-point improvement in the SKT upon EGb 761
treatment and an average deterioration by +1.3 points on placebo
(p<0.001, two sided, ANOVA). EGb 761 was significantly superior to
placebo on all secondary outcome measures, including the NPI and an
activities-of-daily-living scale. Treatment results were essentially similar for
AD and VaD subgroups. The drug was well tolerated; adverse events were
no more frequent under drug than under placebo treatment.
Authors conclusion: The data add further evidence on the safety and
efficacy of EGb 761 in the treatment of cognitive and non-cognitive
symptoms of dementia.
Study
Outcome
Under EGb 761 treatment the SKT total score improved by -3.02.3 and 3.42.3 points in patients with AD and VaD, respectively, whereas the
patients on placebo deteriorated by +1.22.5 and 1.52.2 points,
respectively (p<0.01 for both drug-placebo differences). Significant drugplacebo differences were found for all secondary outcome variables with no
major differences between AD and VaD subgroups. The rate of adverse
events tended to be higher for the placebo group.
Authors conclusion: The subgroup analyses demonstrated that EGb 761
was safe and effective in the treatment of both major types of dementia,
AD and VaD.
Study
Outcome
The mean composite score (frequency x severity) and the mean caregiver
Page 82/120
distress score of the NPI dropped from 21.39.5 to 14.79.5 and from
13.56.7 to 8.75.5, respectively, in the EGb 761-treated patients, but
increased from 21.69.9 to 24.112.8 and 13.46.4 to 13.97.2,
respectively, under placebo (p<0.001). The largest drug-placebo
differences in favour of EGb 761 were found for apathy/indifference,
anxiety, irritability/lability, depression/dysphoria and sleep/nighttime
behaviour.
Authors conclusion: EGb 761 was safe and effective in the treatment of
dementia with neuropsychiatric symptoms.
Study
Indication
Treatment duration
24 weeks
Test product
EGb 761
Single/Daily dosage
120 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=41
number of patients
age
55 years
wash-out
4 weeks
Outcome
Study
Outcome
ITT analysis of the total population: The ITT analysis of the SKT and
estimated AD Assessment Scale-cognition (ADAS-cog) scores revealed a
mean decrease in the total score by -2.1 (95% CI: -2.7; -1.5) points and 2.7 (95% CI: -3.5; -1.9) points, respectively, for the EGb 761 group, which
indicates an improvement in cognitive function. On the contrary, the
placebo group exhibited only a minimal change of -1.0 (95% CI: -1.6; 0.3) and -1.3 (95% CI: -2.0; -0.4) points, respectively. The changes from
baseline differed significantly between treatment groups by 1.1 (SKT) and
1.4 (estimated ADAS-cog) points, respectively (p=0.01). The Clinical
Global Impression of Change favoured the EGb 761 group with a mean
Page 83/120
Study
Indication
Treatment duration
12 months
Test product
EGb 761
Single/Daily dosage
no dose mentioned
Study design
randomised
no
double-blind
no (open)
controlled
yes (standard)
parallel group
yes
multicentre
yes
number of patients
age
65-80 years
wash-out
Outcome
Study
Indication
Treatment duration
52 weeks
Test product
EGb 761
Single/Daily dosage
40 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=6
Page 84/120
Outcome
number of patients
age
45 years
wash-out
2 weeks
ITT analysis: The EGb 761 group had an ADAS-cog score 1.4 points better
than the placebo group (p=0.04) and a Geriatric Depression Scale (GERRI)
score 0.14 points better than the placebo group (p=0.004).
End point analysis: The same patterns were observed with the evaluable
data set in which 27% of patients treated with EGb 761 achieved at least a
4-point improvement on the ADAS-cog, compared with 14% taking placebo
(p=0.005); on the GERRI, 37% were considered improved with EGb 761,
compared with 23% taking placebo (p=0.003). No difference was seen in
the Clinical Global Impression of Change (CGIC). No significant differences
compared with placebo were observed in the number of patients reporting
adverse events or in the incidence and severity of these events.
Authors conclusion: EGb 761 was safe and appears capable of stabilising
and, in a substantial number of cases, improving the cognitive performance
and the social functioning of demented patients for 6 months to 1 year.
Although modest, the changes induced by EGb 761 were objectively
measured by the ADAS-cog and were of sufficient magnitude to be
recognised by the caregivers in the GERRI.
Study
Hofferberth 1989
Indication
Treatment duration
8 weeks
Test product
EGb 761
Single/Daily dosage
40 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
age
53-69 years
wash-out
2 weeks
Outcome
Page 85/120
Study
Indication
Treatment duration
12 weeks
Test product
EGb 761
Single/Daily dosage
40 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
no
number of patients
40
age
55-85 years
wash-out
Outcome
In the EGb 761 group, the values for total Sandoz Clinical AssessmentGeriatric (SCAG) score dropped on average by 9 points, whereas they
remained unchanged in the placebo group (p=0.00005, one-sided, Xtest). Evaluation of the separate items showed an effect particularly on
disturbances of short-term memory and mental awareness as well as on
dizziness as a symptom.
Study
Eckmann 1990
Indication
Treatment duration
6 weeks
Test product
Single/Daily dosage
53.33 mg/160 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
no
number of patients
age
41-71 years
wash-out
Outcome
Study
Indication
Treatment duration
24 weeks
Test product
Single/Daily dosage
Page 86/120
Study design
Outcome
randomised
yes
double-blind
yes
controlled
parallel group
multicentre
number of patients
76
age
50-80 years
wash-out
Korczyn (2007) commented some important aspects on the above mentioned article. The first two
parameters he was missing were that it was not stated who supported the study (industry?) and who
made the statistical calculations. Secondly, the primary and secondary end-points of the study were
not mentioned and the main conclusions (the MMSE) were negative, which was not reflected in the
paper. Also, results a long the way of the study are not shown, at which this is surprisingly as in
studies of cholinesterase inhibitors the strongest effect is seen at 6-12 weeks. In the placebo 4-week
run-in period it was not stated how placebo responders were determined and how many were rejected.
The time point for baseline values was not stated. Last but not least the commentator was missing an
analysis from the completers of the study as there were about 20% dropouts.
Mazza et al. (2007) replied as follows: The study was not supported by any pharmaceutical industry.
The aim of the study was to assess the efficacy of Ginkgo biloba in moderately severe stages of AD.
The results suggested an efficacy of ginkgo comparable with donepezil. Therefore the main conclusions
were not negative, considering that patients treated with ginkgo showed an improvement in attention,
memory and cognitive performance. Results after 6 and 12 weeks showed a significant efficacy and
tolerability of ginkgo compared with donepezil.
Corrao et al. (2007) commented methodological matters on the article by Mazza et al. (2006): There
was a small population sample studied and no effort was made to calculate sample size. Trials with
small population samples have scare sensitivity and can bring to negative results (no differences
between groups). Besides, a drop-out at follow-up 20% comprises the overall quality of a trial. In
this case there was a drop-out of about 21%. Because there exist a lot of different types of ANOVA, it
Page 87/120
must be stated what kind of ANOVA was used. Differences in resulting scores of SKT and MMSE
(obviously not normally distributed) should be evaluated by distribution-free (non-parametric)
statistical methods, like in this case, the Kruskal-Wallis test (a non-parametric ANOVA). The study had
three groups and in no case pair-wise comparisons can be made by a t-test (only used if the study
groups are exclusively two), hence comparison between the study groups need a post hoc evaluation
test like Dwass-Steel-Critchlow-Fligner or Conover-Inman procedures. For all these reasons, no
statements could be made on the efficacy of the two treatments. Moreover, this study cannot evaluate
tolerability of Ginkgo biloba due to the small sample size and the short-time follow-up. Having pointed
out these aspects, this study has scientific value, but readers should be advised of all these
considerable limitations.
Reply by Mazza et al. (2007): It was already outlined in the Discussion and conclusions section
that larger samples of patients should be considered to confirm these results. In the authors opinion
this drop-out rate clearly reflects peculiar clinical features of enrolled patients, as psychiatrists and
neurologists working in the field of dementia know. As for considerations regarding the statistical
analysis section, a preliminary analysis of the data was conducted using the Shapiro-Wilk normality
test (W), which checks of normal distribution. In the present case W was not significant, so the
scientists were not obliged to use non-parametric methods. The authors do not assume that the results
of this test is clear evidence of normality or non-normality, but, in such perspective, we used t-test
comparing each group in two different times (baseline and after 24 weeks).
Study
Indication
Treatment duration
22 weeks
Test product
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (donepezil)
parallel group
yes
multicentre
n=4
number of patients
Outcome
age
50 years
wash-out
8 weeks
Changes from baseline to week 22 and response rates were similar for all
three treatment groups with respect to all outcome measures (SKT, NPI,
total score and ADL sub-score of the GBS, HAMD, CDT and Verbal Fluency
Test). An apparent tendency in favour of combination treatment warrants
further scrutiny. Compared to donepezil mono-therapy, the adverse event
rate was lower under EGb 761 treatment and even under the combination
treatment.
Authors conclusion: Three hypotheses were developed that will have to be
Page 88/120
Study
Indication
Treatment duration
26 weeks
Test product
EGb 761
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=44
number of patients
Outcome
age
wash-out
4 weeks
Study
Indication
Treatment duration
24 weeks
Test product
EGb 761
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
yes
number of patients
Page 89/120
Outcome
age
50 years
wash-out
Study
Outcome
Study
Indication
Treatment duration
6 months
Test product
EGb 761
Single/Daily dosage
60 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
number of patients
176
age
55 years
wash-out
Outcome
Ginkgo biloba did not have a significant effect after 6 months on either the
ADAS-cog score (p=0.392), the participant-rated QOL-AD score (p=0.787)
nor the carer-rated QOL-AD score (p=0.222).
Page 90/120
Study
Indication
Treatment duration
12 weeks
Test product
EGb 761
Single/Daily dosage
240 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=5
number of patients
300
age
45-65 years
wash-out
Outcome
Study
Indication
Treatment duration
Test product
EGb 761
Single/Daily dosage
120 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
yes (n=5)
number of patients
age
75 years
wash-out
Outcome
Page 91/120
1.39; p=0.11). EGb 761 also had no effect on the rate of progression to
dementia in participants with MCI (HR, 1.13; 95% CI, 0.85-1.50; p=0.39).
Authors conclusion: EGb 761 at 120 mg 2 times daily was not effective in
reducing either the overall incidence rate of dementia or AD incidence in
elderly individuals with normal cognition or those with MCI.
Study
Indication
Treatment duration
6 weeks
Test product
Ginkgo biloba fresh plant extract (DER 3-5:1; extractant 65% ethanol V/V;
produced in Switzerland)
Single/Daily dosage
90 mg/180 mg
Study design
randomised
double-blind
no (open)
controlled
parallel group
multicentre
n=11
number of patients
59
age
>60 years
wash-out
Outcome
After 6 weeks the SF-12 mental score had increased significantly from
48.310.1 to 51.37.9, whereas the sf-12 body score (44.59.2 to
45.38.1) and the DemTect score (15.92.0 to 16.02.3) had not
changed significantly. About half of all patients experienced an
improvement in their memory and their ability to concentrate, as well as a
decrease in symptoms of forgetfulness. The majority of investigators and
patients judged the treatment to be effective.
Authors conclusion: This newly developed, holistic fresh leaf extract of
Ginkgo biloba is a safe, effective, and, at least, adjuvant treatment option
for patients with mild cognitive impairments.
Study
Indication
Treatment duration
5 years
Test product
EGb 761
Single/Daily dosage
120 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
n=13
number of patients
age
70 years
wash-out
Page 92/120
Outcome
Over 5 years, 61 participants in the ginkgo group had been diagnosed with
probable Alzheimers disease (1.2 cases per 100 person-years) compared
with 73 participants in the placebo group (1.4 cases per 100 person-years;
hazard ratio [HR] 0.84, 95% CI 0.6-1.18; p=0.306), but the risk was not
proportional over time. Incidence of adverse events was much the same
between groups. Death and stroke rate also incidence of other
haemorrhagic or cardiovascular events did not differ between groups.
Authors conclusion: Long-term use of standardised Ginkgo biloba extract
in this trial did not reduce the risk of progression to Alzheimers disease
compared with placebo.
Study
Indication
Treatment duration
24 weeks
Test product
Single/Daily dosage
Study design
Outcome
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
n=22
number of patients
age
55-86 years
wash-out
4 weeks
In the subjective test, the EMCT, the Rey 1 and Rey 2 no significant
differences in improvement in time between the groups were observed. In
the Benton test increases of 18%, 26% and 11% (expressed as percentage
of baseline scores) were observed in the HD, LD and placebo, respectively
(MANOVA; p=0.0076). No substantial correlation was observed between
subjective perception of the severeness of memory complaints and the
objective test results. There were no differences in the amount of side
effects between groups.
Authors conclusion: It was demonstrated that a Ginkgo biloba
alcohol/water extract is effective in elderly individuals with cognitive
impairment.
Study
Kaschel 2011
Indication
To investigate the effects of EGb 761 on memory and the specificity of such
effects on distinct memory functions
Treatment duration
6 weeks
Test product
EGb 761
Single/Daily dosage
240 mg/240 mg
Page 93/120
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
no
number of patients
Outcome
age
45-56 years
wash-out
at least 8 weeks
Study
Indication
Treatment duration
42 months
Test product
Single/Daily dosage
80 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
118
age
85 years
wash-out
Outcome
Page 94/120
Page 95/120
Authors conclusion: The bivariate random effect meta-analysis of 6 clinical studies demonstrated that
standardised Ginkgo biloba extract could significantly improve the cognitive function of dementia
disorders with the treatment period of 6 months when baseline risk was considered in assessing the
efficacy of standardised Ginkgo biloba extract.
Weinmann et al. (2010): Meta-analysis of clinical studies of the effects of Ginkgo biloba in dementia
ITT/LOCF change scores for cognition outcomes (ADAS-cog, SKT):
Page 96/120
patients with AD, there was a statistically significant advantage of Ginkgo biloba compared to placebo.
In a situation, where the clinical significance of the moderate effects of cholinesterase inhibitors and
memantine as symptomatic treatments is increasingly been questioned, Ginkgo biloba may not be an
inferior treatment option for a considerable number of people with mild to moderate dementia.
However, direct comparisons are lacking. A major multicenter study to compare the relative
effectiveness of Ginkgo biloba and cholinesterase inhibitors for different dementia subgroups appears
justified.
Yang et al. (2011): Meta-analysis of Ginkgo biloba extract for the treatment of AD
Meta-analysis of MMSE scores:
Authors conclusion: Ginkgo biloba extract shows good therapeutic effects for mild and moderate AD.
Solomon and Michalczuk (2009) discussed the conflicting results of Ginkgo biloba studies emerged
from the fact that there is no agreed upon set of standards by which to judge the efficacy of
complementary and alternative medicines (CAM). On the basis of having no generally accepted
guidelines to standardise the types of studies that are conducted in the field of cognition enhancement
in both healthy elderly and patients with AD and other dementing disorders, the authors suggested a
roadmap for establishing guidelines for the evaluation of CAM in cognition. They applied these
guidelines to the conflicting literature on Ginkgo biloba to determine whether they might help resolve
the conflicting results. The criteria suggested in the guidelines of this article are the generally accepted
standards by both United States [draft guideline for the evaluation of antidementia compounds (Leber
1990) of the Division of Pharmacologic Drug Actions of the U.S. FDA] and European regulatory
agencies [guidelines for evaluating the efficacy (and safety) of treatments for AD and other dementias]
for clinical research. Applying the proposed guidelines to some of the literature that have led to the
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 97/120
controversy results invites the conclusion that Ginkgo biloba has no discernable benefits on cognition in
either patients with AD, in preventing AD, or in the healthy elderly. The clinical implications of this
conclusion are that Ginkgo biloba should not be recommended to healthy elderly or patients with AD.
The authors themselves make assumptions about the criteria suggested in this article (which are the
generally accepted standards by both U.S. and European regulatory agencies for clinical research) used
to judge studies. A second and related question is whether the evidence regarding ginkgo on cognition
is sufficient to conclude that the compound is not effective, and further research is unlikely to change
this conclusion and therefore not necessary. In summary the authors would suggest that if Ginkgo
biloba had to meet present regulatory guidelines to be marketed, it would be with drawn from
development.
Lders et al. (2012) summarised the increasing knowledge that has been obtained from clinical
studies about the impact that vascular factors have on cognitive function and dementia (vascular
dementia). Due to demographic reasons and still insufficient control of all vascular risk factors,
dementia and associated problems are of increasing importance and will have impact on economical
and social develpoment in most countries. The incidence of cognitive impairment and dementia will
increase exponentially. As long as no causal therapy for dementia exists, diagnosis and control of risk
factors for dementia will need much more attention. Hypertension is not only the most important risk
factor for stroke that often leads to dementia but also for silent brain infarcts, which are also
associated with onset of dementia. Uncontrolled hypertension is associated with cognitive impairment
and sufficient control of hypertension in middle-aged patients can reduce the risk of dementia in older
ages. Nevertheless, treatment of all other risk factors, such as diabetes mellitus, smoking,
hyperlipidemia, aterial fibrillation, is important to reduce the onset of not only vascular but also
Alzheimer dementia.
Healthy participants:
Study
Indication
Treatment duration
Test product
LI 1370
Single/Daily dosage
120 mg/120 mg
Study design
randomised
no
double-blind
no
controlled
parallel group
yes
multicentre
number of patients
Outcome
age
>60 years
wash-out
no
There were significant differences in the mean overall line analogue rating
scale (LARS) and self-rating activities of daily living scale (SR-ADL) scores
between the four treatment combination groups at the end of the follow-up
period. A factor analysis of the LARS revealed two factors, mood and
alertness. When scores from each of the treatment groups were
examined over the whole 10 month period it was evident that the ratings
of overall competence in the SR-ADL and both factors of the LARS were
diminished on the cessation of treatment with LI 1370, and improved when
Page 98/120
Authors conclusion: The reviewed studies confirm the efficacy of EGb 761. In 6 of 9 studies, a relevant
superiority compared to placebo could be demonstrated. The pooled evaluation of all studies showed
the clinical relevance of the therapeutic effects of EGb 761 as well. With a good to very good
tolerability, the benefit/risk ratio is consequently in favour of a therapy with EGb 761 in patients with
PAOD stage II (according to Fontaine).
Nicola et al. 2009: In the abstract of the Cochrane Review on Ginkgo biloba for intermittent
claudication (Review) the results are as follows: Fourteen trials with a total of 739 participants were
included. Eleven trials involving 477 participants compared Ginkgo biloba with placebo and assessed
the absolute claudication distance. Following treatment with Ginkgo biloba at the end of the study the
absolute claudication distance increased with an overall effect size of 3.57 kilocalories (CI -0.10 to
7.23, p=0.06), compared with placebo. This translates to an increase of just 64.5 (CI -1.8 to 130.7)
meters on a flat treadmill with an average speed of 3.2 km/h. Publication bias leading to missing data
or negative trials is likely to have inflated the effect size.
Forest plot of clinical studies comparing the absolute claudication distance (expressed as kilocalories)
at the end of the study
Page 99/120
Authors conclusion: There is no evidence that Ginkgo biloba has a clinically significant benefit for
patients with PAD.
Pittler and Ernst (2000) included eight randomised, placebo-controlled, double-blind trials in a
meta-analysis. In three of these trials EGb 761 was applied. There is no concrete information on the
other extracts. A significant difference in the increase in pain-free walking distance in favour of Ginkgo
biloba (weighed mean difference: 34 meters, 95% confidence interval [CI]: 26 to 43 meters) was
determined. In studies using similar methodological features (ergometer speed: 3 km/h, inclination:
12%) this difference was 33 meters in favour of Ginkgo biloba (95% CI: 22 to 43 meters). Concerning
to the authors these results suggest that Ginkgo biloba extract is superior to placebo in the
symptomatic treatment of intermittent claudication. However, the size of the overall treatment effect is
modest and of uncertain clinical relevance.
Letzel and Schoop (1992): Clinical trials on the efficacy of EGb 761 and pentoxifylline were
assessed. On average an increase of 45% (EGb 761) or 57% (pentoxifylline) in relation to initial values
was found.
Study
Indication
Treatment duration
4 months
Test product
EGb 761
Single/Daily dosage
60 mg/300 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
number of patients
62
age
wash-out
Outcome
Page 100/120
Study
Indication
Treatment duration
24 weeks
Test product
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
age
wash-out
6 weeks
Outcome
Study
Indication
PAD
Treatment duration
24 weeks
Test product
Single/Daily dosage
120 mg/240 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (controlled)
parallel group
yes
multicentre
number of patients
age
50-80 years
wash-out
Outcome
Page 101/120
Study
Wu et al. 2007
Indication
Treatment duration
one-time administration
Test product
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
age
wash-out
Outcome
Healthy participants:
Study
Indication
Treatment duration
6 months
Test product
Single/Daily dosage
80 mg/80 mg
Study design
randomised
yes
Page 102/120
double-blind
controlled
parallel group
multicentre
no
number of patients
age
wash-out
Outcome
Study
Wu et al. 2008
Indication
To test the effects of Ginkgo biloba extract (GBE) on LAD blood flow and
endothelium-dependent brachial artery FMD
Treatment duration
one-time administration
Test product
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
age
wash-out
Outcome
GBE significantly increased LAD blood flow in MDPV, MSPV and DTVI
compared with the placebo group (19.1613.91% vs. 0.302.55%,
17.7614.56% vs. 0.532.32%, and 21.7316.13% vs. 0.812.33%,
MDPV, MSPV, and DTVI improvement from baseline, respectively,
p<0.01).Brachial artery FMD was also increased by 56.03% (from
7.212.52% to 11.283.95%, p<0.01). A linear correlation was found
between the percentage change in MDPV, MSPV, or DTVI of LAD blood flow
and the percentage change in brachial artery FMD following treatment with
GBE (r=0.538, 0.366, or 0.573, respectively, p<0.01, p<0.05, or p<0.01).
Page 103/120
Indication
Treatment duration
12 weeks
Test product
LI 1370
Single/Daily dosage
50 mg/150 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
number of patients
age
18-70 years
wash-out
Outcome
Study
Indication
Treatment duration
2 weeks
Test product
Single/Daily dosage
14.6 mg/29.2 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
no (but crossover)
multicentre
number of patients
20
age
41-77 years
wash-out
Outcome
Page 104/120
Study
Indication
Treatment duration
Test product
EGb 761
Single/Daily dosage
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
yes
multicentre
number of patients
60
age
wash-out
Outcome
For the primary outcome measure, significant superiority of EGb 761 over
placebo was demonstrated in the ITT analysis data set after 4, 8 and 12
weeks of out-patient treatment (p<0.05, 1-tailed), although the absolute
treatment group difference was moderate. The results were supported by
the secondary outcome measures for efficacy (e.g. decreased hearing loss,
improved self-assessment of subjective impairment). During out-patient
treatment, there were no adverse events under EGb 761.
Authors conclusion: A combination of infusion therapy followed by oral
administration of EGb 761 appears to be effective and safe in alleviating
the symptoms associated with tinnitus aurium.
Study
Indication
Treatment duration
12 weeks
Test product
EGb 761
Single/Daily dosage
40 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
no
number of patients
40
age
55-85 years
wash-out
Outcome
The symptom of tinnitus was specifically asked for and their specification
was documented with the aid of a four-stage rating scale.
In the group receiving active substance superior effect was shown in the
symptom of tinnitus (p=0.035).
Page 105/120
Rejali et al. (2004): In the review it was concluded that there is now level 1a evidence that Ginkgo
biloba does not benefit patients with tinnitus.
Hilton and Stuart (2010): The authors conclusion in the abstract in the Cochrane review Ginkgo
biloba for tinnitus is: The limited evidence did not demonstrate that Ginkgo biloba was effective for
tinnitus which is a primary complaint. There was no reliable evidence to address the question of
whether Ginkgo biloba is effective for tinnitus associated with cerebral insufficiency.
Smith et al. (2005) concluded in the review: Although there are some clinical trials that have yielded
positive results from the use of Ginkgo biloba extracts (), these studies are few and have been
limited either by design flaws (), the small size of the significant effect (), or else the results have
not been published in peer-reviewed journals () and therefore the quality of the research is not
proven. On the other hand, the two most systematic clinical trials, both of which are double-blind and
placebo-controlled, and are published in respected peer-reviewed journals, have yielded negative
results and suggest that Ginkgo biloba extracts are of little more use in the treatment of tinnitus than
placebo. This is an important conclusion because treatments that do not have therapeutic efficacy not
only waste money but can prevent patients from seeking therapy that is efficacious. Furthermore,
the unsupervised use of Ginkgo biloba extracts with other medications could lead to adverse side
effects (e.g. haemorrhagic effects of concurrent use of aspirin) which are unnecessary and not justified
in terms of therapeutic benefit.
4.2.2.4. Vertigo
Study
Indication
Atherosclerosis-related vertigo
Treatment duration
8 weeks
Test product
Single/Daily dosage
40 mg/120 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (vertigoheel)
parallel group
yes
multicentre
n=13
number of patients
age
60-80 years
wash-out
Outcome
Page 106/120
Study
Indication
Treatment duration
3 months
Test product
EGb 761
Single/Daily dosage
80 mg/160 mg
Study design
randomised
yes
double-blind
yes
controlled
yes (placebo)
parallel group
multicentre
n=3
number of patients
age
wash-out
Outcome
Page 107/120
respectively. The total VASI score improved by 0.5 (p=0.021) from 5.0 to 4.5, which indicated an
average repigmentation of vitiligo lesions of 15%. The progression of vitiligo stopped in all participants.
VETF total vitiligo lesion area decreased 0.4% (p=0.102) from 5.9 to 5.6 from baseline to week 12.
VETF staging score improved by 0.7 (p=0.10) from 6.6 to 5.8, and the VETF spreading score improved
by 3.9 (p<0.001) from 2.7 to -1.2. There were no statistically significant changes in safety assessed by
serum coagulation factors (platelets, PTT, INR).
Esposito and Carotenuto (2011): The study has investigated administration of ginkgolide B as
preventive treatment in primary headache in young patients. Ginkgolide B was considered as a
pharmacological aid for the treatment of migraine in adult patients because its peculiar modulation of
the glutamatergic transmission in the CNS and on platelet activating factor (PAF). 119 school-aged
patients (mean age 9.71.42) received ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium complex
(not further specified) twice a day for 3 months. At the end of the study the mean frequency per
month of migraine was significantly decreased (9.714.33 vs. 4.533.96 attacks; p<0.001).
Usai (2011): Another study investigated the effect of ginkgolide B as preventive treatment to confirm
the long-term utility on a group of young patients suffering from primary headache such as migraine
without aura. In an open-label trial 30 patients aged between 8 and 18 (mean age 13.52.2) were
treated orally with a combination of ginkgolide B 80 mg, coenzyme Q10 20 mg, vitamin B2 1.6 mg and
magnesium 300 mg twice per day for 3 months. The number of monthly migraine attacks was reduced
after 3 months of treatment in relation to pre study baseline. At 1-year follow-up mean number of
days of headaches per month decreased significantly from 7.24.3 to 1.61.7 (p 0.000).
Cala et al. (2003) examined the use of herbal therapy in children or adolescents receiving care for a
depressive disorder or Attention-Deficit-Hyperactivity Disorder (ADHD) (with or without comorbidities).
The main outcome measure was primary caregivers self-report of the use of herbal therapy in their
children using a 23-item questionnaire on 117 parents or caregivers of patients younger than 18
years (mean age 10.93.1 years). The mean age at onset of a psychiatric condition was 8.13.3
years. 110 patients (94.0%) were being treated with prescription drugs at the time of the study. The
overall lifetime prevalence of herbal therapy in patients was 23 (19.6%) of the 117 patients.
Recommendations from a friend or relative resulted in the administration of herbal medicines by 61%
of 23 caregivers. No caregivers reported that a recommendation from a health care professional or that
an adverse effect from conventional drug was the primary reason herbal therapy was tried in their
children. Herbal medicines were given most frequently for a behavioural condition as reported by 8 of
23 caregivers, with Ginkgo biloba (not further specified) most prevalent (26%). 15 caregivers (65%) of
23 who gave their children herbal medicines thought they were effective, and of these, all perceived
herbal therapy to be at least somewhat if not very effective. None of the 23 caregivers reported any
adverse effects in their children from herbal medicines. However, decreased effectiveness or
ineffectiveness was the most common reported reason for stopping herbal therapy.
Salehi et al. (2010) evaluated their hypothesis that Ginkgo biloba would be beneficial for treatment
of Attention-Deficit-Hyperactivity Disorder (ADHD) in a randomised, double-blind, parallel group
comparison of Ginkgo biloba (Ginko T.D. Tolidaru, Iran) and methylphenidate. Fifty outpatients (39
boys and 11 girls) aged between 6-14 years with DSM-IV-TR diagnosis of ADHD were randomly
assigned to receive treatment using tablet of ginkgo T.D. at a dose of 80-120 mg/day depending on
weight (80 mg/day for <30 kg and 120 mg/day for >30 kg) (group 1) or methylphenidate at a dose of
20-30 mg/day depending on weight (20 mg/day for <30 kg and 30 mg/day for >30 kg) (group) for
6 weeks. The principal measure of outcome was the Teacher and Parent ADHD Rating Scale-IV.
Patients were assessed at baseline and at 21 and 42 days of treatment. Significant differences were
observed between the two groups. The changes at the end of the studycompared to baseline were: 6.5211.43 (meanSD) and -15.9211.44 (meanSD) for Ginko T.D. and methylphenidate,
Page 108/120
respectively for Parent ADHD Rating Scale. The changes at the endpoint compared to baseline were: 0.846.79 (meanSD) and -14.048.67 (meanSD) for Ginko T.D. and methylphenidate, respectively
for Teacher ADHD Rating Scale. The difference between the two groups in the frequency of side effects
was not significant except for decreased appetite, headache and insomnia that were observed more
frequently in the methylphenidate group.
Biggs et al. (2010): In a secondary analysis of the Ginkgo Evaluation of Memory (GEM) study Ginkgo
biloba and risk of cancer was analysed. Evidence from in vitro and in vivo studies suggests that Ginkgo
biloba has cancer chemopreventive properties, but epidemiological evidence is sparse. 3069 subjects
(75 years) participated in the GEM study which had a randomised, double-blind and placebocontrolled design. Participants received 120 mg EGb 761 two times daily or placebo. The results show
there were 148 cancer hospitalisations in the placebo group and 162 in the EGb 761 group (HR, 1.09;
95% CI, 0.87-1.36; p=0.46). Among the site-specific cancers analysed, we observed an increased risk
of breast (HR, 2.15; 95% CI, 0.97-4.80; p=0.06) and colorectal (HR, 1.62; 95% CI, 0.92-2.87;
p=0.10) cancer, and a reduced risk of prostate cancer (HR, 0.71; 95% CI, 0.43-1.17; p=0.18). In
conclusion, these results do not support the hypothesis that regular use of Ginkgo biloba reduces the
risk of cancer.
Page 109/120
was assumed at a daily dose of 360 mg of EGb 761. Also inducing effects for Ginkgo biloba extracts
other than EGb 761 on CYP2C19 were observed.
The inhibitory effect of Ginkgo biloba extract on the pharmacokinetics of the P-gp substrate talinolol
was studied in healthy volunteers. The observed increase of C max by 33% and AUC by 21% without
any significant alterations in T max and T 1/2 of talinolol supports the hypothesis of Blonk et al. (2012):
that a possible explanation for the increase in C max and bioavailability of a drug when combined with
EGb 761 could be the inhibition of P-gp by EGb 761. These findings could also be a reflection of
individual variation in the inhibitory potential of P-gp by Ginkgo biloba. The expression and transport
activities may differ between individuals due to genetic variation in the highly polymorphic MDR1 gene.
Therefore, the extent of the inhibition of P-gp may vary accordingly.
One study examining clinical pharmacokinetic interactions of Ginkgo biloba extract and nifedipine, a
calcium-channel blocker, indicated individual increase in C max by concomitant administration. The two
subjects had severer and longer-lasting headaches with dizziness or hot flushes in combination.
From two reviews clinical pharmacological interactions of Ginkgo biloba with alprazolam, haloperidol,
trazodone, omeprazole, aspirin, ibuprofen, nifedipine, warfarin, antiepileptics, antidiabetics, diuretics
and nonsteroidal anti-inflammatory drugs were mentioned.
Clinical efficacy
The EMA Guideline on Medicinal Products for the Treatment of Alzheimers Disease and Other
Dementias (2009) focuses on the development of new medicinal products for the treatment of
dementia and its subtypes. Other guidelines focus more on clinical aspects and care of people with
dementia. Recommendations from the article Management of dementing disorders, conclusions from
the Canadian consensus conference on dementia (1999) have been developed with particular
attention to the context of primary care, and are intended to support family physicians in their ongoing
assessment and care of patients with dementia. Also the German guideline on dementia (S3-Leitlinie
Demenzen [2009]) gives statements to prevention, diagnostic and therapy of dementia as well as to
mild cognitive impairment. The aim is to give assistance to persons who treat and care patients with
dementia and their relatives in decision making of diagnostic, therapy, care and consultation. Besides
pharmacological therapy special emphasis was placed on psychosocial intervention. A British National
Institute for Health and Clinical Excellence (NICE) guideline dementia (2012) makes
recommendations for the identification, treatment and care of people with dementia and the support of
carers. Settings relevant to these processes include primary and secondary healthcare, and social care.
In addition the Scottish Intercollegiate Guidelines Network (SIGN) published a national clinical
guideline Management of patients with dementia (2006). It covers also diagnosis, nonpharmacological interventions, and pharmacological interventions in people with dementia. The
obligation for medicinal products with indications in the field of neurological disorders to apply for a
marketing authorisation via the centralised procedure is addressing new substances.
The results of the IQWIG report 2008 support the use of ginkgo containing products in patients with
mild, moderate, or severe dementia, which includes AD and mixed-type dementia (AD and VaD). The
following studies were analysed in the report: Schwabe (2008), Napryeyenko and Borzenko (2007),
Yancheva et al. (2006), Schneider et al. (2005), LeBars et al. (1997), Kanowski et al. (1996), Digger
(2007). It was evidenced that 240 mg ginkgo extract EGb 761 has a benefit on activities of daily
living. Further, hints of a benefit on cognitive function and general psychopathological symptoms
are mentioned. However, the conclusion that ginkgo has a beneficial effect is based on very
heterogeneous results. Therefore no summarising conclusion was made on the potential effect size.
Additionally there is a sign that this benefit is only present in patients with accompanying
psychopathological symptoms. Moreover, it needs to be considered that results were strongly affected
Page 110/120
by 2 studies conducted in an Eastern European health-care setting with specific patient populations
(among other things, patients with a high rate of accompanying psychopathological symptoms).
Meanwhile two recent studies are published by Herrschaft et al. (2012) and Ihl et al. (2010) that are
supportive for the monograph relevant indication as well. These studies include patients with mild to
moderate dementia (AD or VaD) with neuropsychiatric symptoms.
According to the complexity of the disease partial aspects should be considered in the therapeutical
concept of dementia. Besides others the factor quality of life of patients and caregivers should be
included in these considerations. The IQWIG report 2008 and two more recent studies (Grass-Kapanke
et al. (2011) and Heinen-Kammerer et al. (2005)) addressed this parameter of improving the patients
and caregivers condition.
On the part of the EMA it is noticed that the Guideline on Medicinal Products for the Treatment of
Alzheimers Disease and Other Dementias is under discussion (Concept paper on no need for revision
of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias).
It is said in the guideline, that despite the rapid progress in understanding of the neurobiology and
pathophysiology of AD, the most common form of dementia, only cholinesterase-inhibitors and
memantine have been approved for the symptomatic treatment with overall limited clinical
improvement and no product has been approved for disease modification in any neurodegenerative
disorder. Furthermore, it is stated that new diagnostic criteria and choice of outcome parameters
should be revised according to the complex pathomechanism of dementia diseases.
Also the long standing use with ginkgo containg products should be kept in mind.
In summary, clinical trials investigating indications in the therapeutic area of tinnitus and claudication
intermittens are not convincing to support well-established use of this application. There are
appropriate studies which support the usage of Ginkgo biloba preparations in the therapeutic area of
mild dementia demonstrating improvement of cognitive impairment and of quality of life. The most
relevant clinical trials have been performed including patients of 50 years and above. The data
particularly indicate that improvements were observed in patients with neuropsychiatric diagnostics.
5. Clinical Safety/Pharmacovigilance
5.1. Overview of toxicological/safety data from clinical trials in humans
See section 4.1. and 4.2.
Furthermore, as reviewed by Oberpichler-Schwenk (1995) no case of overdose has been reported
so far. The available data prove a low toxicity of Ginkgo biloba extract, whereby it should be keep in
mind that these toxicological data were identified with the special extract EGb 761.
Page 111/120
studies regarding adverse event reporting was done. Only those trials which mentioned the specific
adverse event have been considered when calculating the frequencies. A frequency calculation was
performed for the most reported adverse events which are: headache, dizziness, respiratory tract
infection, hypertension/blood pressure increased, gastrointestinal complaints (diarrhoea, abdominal
pain and nausea), angina pectoris and tinnitus. It should be keep in mind that the adverse events
profiles for the Ginkgo extract preparations and placebo groups were similar or even higher rates exist
in the placebo group.
For the adverse events mentioned in the monograph in the traditional use part, data based on
information of the extract are given. There are no reports of adverse events regarding the traditionally
used powder. Therefore the possible adverse events are transferred from the WEU part without the
given frequencies.
In Germany currently (June 20, 2012) over 400 adverse reactions reports in nearly all organ systems
are labelled according to the Federal Institute for Drugs and Medical devices (BfArM) database
for adverse events. The following adverse events were most frequently mentioned (more than 20
reports for each adverse event): dizziness, headache, pruritus, vomiting, nausea, diarrhoea, chills,
rash and erythema.
Snitz et al. (2009) stated in their analyses of the GEM study: The adverse event profiles for the
Ginkgo biloba and placebo groups were similar and the rates of serious adverse events, including
mortality and incidence of coronary heart disease, stroke of any type, and major bleeding, did not
differ significantly.
Kuller et al. (2010): In the GEM study cardiovascular disease (CVD) was a secondary outcome. The
identification and classification of CVD was based on methods used in the Cardiovascular Health Study.
Differences in time to event between Ginkgo biloba and placebo were evaluated using Cox proportional
hazards regression adjusted for age and sex. There were 355 deaths in the study, 87 due to coronary
heart disease with no differences between Ginkgo biloba and placebo. There were no differences in
incident myocardial infarction (n=164), angina pectoris (n=207), or stroke (151) between Ginkgo
biloba and placebo. There were 24 haemorrhagic strokes, 16 on Ginkgo biloba and 8 on placebo (not
significant). There were only 35 peripheral vascular disease events, 12 (0.8%) on Ginkgo biloba and
23 (1.5%) on placebo (p=0.004, exact test). Most of the peripheral vascular disease cases had either
vascular surgery or amputation. In conclusion, there was no evidence that Ginkgo biloba reduced total
or CVD mortality or CVD events. There were more peripheral vascular disease events in the placebo
arm. Ginkgo biloba cannot be recommended for preventing CVD. Further clinical trials of peripheral
vascular disease outcomes might be indicated.
DeKosky et al. (2008): Secondary objectives in the GEM study were to evaluate the effect of Ginkgo
biloba among other things on total mortality and incidence of cardiovascular disease (CVD) (defined as
the combined incidence of confirmed coronary heart disease, angina, stroke, transient ischemic attack,
coronary artery bypass surgery, or angioplasty; incidence was confirmed by review of the participants
medical record after self-report). There were 379 deaths from any cause. The adverse event profiles
for EGb 761 and placebo were similar and there were no statistically significant differences in the rate
of serious adverse events. The mortality rate was similar in the 2 treatment groups (HR, 1.04; 95% CI,
0.85-1.26; p=0.72). There were no differences in the incidence of coronary heart disease (myocardial
infarction, angina, angioplasty, or coronary artery bypass graft) or stroke of any type by treatment
group. Of particular note rates of major bleeding did not differ between the treatment groups (HR,
0.97; 95% CI, 0.77-1.23; p=0.81), and bleeding incidence did not differ for individuals taking aspirin
and assigned to either EGb 761 or placebo (rates of 1.98 and 1.76 per 100 person-years, respectively,
p=0.44). Although there were twice as many haemorrhagic strokes in the EGb 761 group compared
with the placebo group (16 vs. 8), the number of cases was small and nonsignificant in the analysis.
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 112/120
Biggs et al. (2010): In a secondary analysis of the Ginkgo Evaluation of Memory (GEM) study Ginkgo
biloba and risk of cancer was analysed. Evidence from in vitro and in vivo studies suggests that Ginkgo
biloba has cancer chemopreventive properties, but epidemiological evidence is sparse. 3069 subjects
(75 years) participated in the GEM study which had a randomised, double-blind and placebocontrolled design. Participants received 120 mg EGb 761 two times daily or placebo. The results show
there were 148 cancer hospitalisations in the placebo group and 162 in the EGb 761 group (HR, 1.09;
95% CI, 0.87-1.36; p=0.46). Among the site-specific cancers analysed, we observed an increased risk
of breast (HR, 2.15; 95% CI, 0.97-4.80; p=0.06) and colorectal (HR, 1.62; 95% CI, 0.92-2.87;
p=0.10) cancer, and a reduced risk of prostate cancer (HR, 0.71; 95% CI, 0.43-1.17; p=0.18). In
conclusion, these results do not support the hypothesis that regular use of Ginkgo biloba reduces the
risk of cancer.
Brinkley et al. (2010) based the article on data from the GEM study. The GEM study included 3069
participants with a mean age of 79 years. The effects of EGb 761 on blood pressure and incident
hypertension were determined. It was also examined whether the treatment effects are modified by
baseline hypertension status. At baseline, 54% of the study participants were hypertensive, 28% were
prehypertensive, and 17% were normotensive. Over a median follow-up of 6.1 years, there were
similar changes in blood pressure and pulse pressure in the Ginkgo biloba and placebo groups.
Although baseline hypertension status did not modify the antihypertensive effects of Ginkgo biloba, it
did influence the changes in blood pressure variables observed during follow-up, with decreases in
hypertensives, increases in normotensives and no changes in prehypertensives. Among participants
who were not on antihypertensive medications at baseline, there were no differences between
treatment groups in medication use over time, as the odds ratio (95% CI) for being a never-user in the
Ginkgo biloba group was 0.75 (0.48-1.16). The rate of incident hypertension also did not differ
between participants assigned to Ginkgo biloba vs. placebo (HR, 0.99, 95% CI, 0.84-1.15). In
conclusion, the data indicate that Ginkgo biloba does not reduce blood pressure or the incidence of
hypertension in elderly men and women.
Halil et al. (2005) conducted the study to assess the effects of EGb 761 on PFA-100 in vitro bleeding
time in elderly patients with mild cognitive impairment. 40 patients aged 65-79 years received 80 mg
EGb 761 three times daily for 7 days. There was no statistically significant prolongation in PFA-100 in
vitro bleeding time or coagulation parameters in patients receiving EGb 761 after 7 days. The data
about the safety of EGb 761 from the point of primary haemostasis in our elderly patient population
with mild cognitive impairment casts hope for the future management of this difficult-to-treat
population with the promising ginkgo extracts.
Naccarato et al. (2012): described a case report of a potential drug-herbal interaction between
Ginkgo biloba (supplement of 300 mg daily) and Efavirenz (EFV), an antiretroviral drug, which is
metabolised by CYP3A and CYP2B, in a patient that was maintained on the same regimen for 10 years.
Using the Drug Interaction Probability Scale proposed by Horn et al. to evaluate drug interaction cases,
the proposed causal relationship of virological breakthrough due to a drug interaction between Ginkgo
biloba and EFV was calculated as probable. The authors suggested an inducing effect of Ginkgo biloba
on EFV metabolism leading to virological breakthrough, based on the influence of Ginkgo biloba on the
CYP450 biotransformation.
Granger (2001) describes two patients with well-controlled epilepsy, compliant with their antiepileptic medication (1200 mg sodium valproate daily), who developed seizures within two weeks of
using Ginkgo biloba products (not further specified, 120 mg daily). Both patients took other
medications. Other medications from one patient were temazepam, aspirin and ramipril and from the
other one aspirin, rivastigmine and thioridazine. After cessation of the herbal remedy, both the
Page 113/120
patients remained seizure-free without any increase in the dosage of antiepileptic medication or
change of the other medications.
Healthy participants
Keheyan et al. (2011) randomised 14 young healthy men in a placebo-controlled and crossover trial.
Participants received EGb 761 and placebo to investigate whether a single dose of EGb 761 can
improve vascular function. The arterial stiffness (DVP-SI) was slightly higher 2 hours after EGb 761
administration compared to placebo (p<0.05). There was no effect of either EGb 761 or placebo on
pressure wave reflection (DVP-RI), peripheral augmentation index (pAIx), blood pressure and heart
rate.
Khler et al. (2004): This randomised, crossover trial was conducted to investigate the influence of
EGb 761 on bleeding time, coagulation parameters, and platelet activity. 50 healthy male volunteers
received 120 mg two times daily EGb 761 and placebo. The two treatment phases were separated by
an at least 3 weeks wash-out period. The study did not reveal any evidence to substantiate a causal
relationship between the administration of EGb 761 and haemorrhagic complication. As regards
treatment tolerability, there were no interpretable differences between EGb 761 and placebo except for
slight increase of gastrointestinal complaints during administration of the herbal extract.
Kudolo et al. (2004) examined the effect of EGb 761 administration on arachidonic acid (AA)
metabolism in platelets. In this randomised, double-blind, placebo-controlled and crossover study 12
healthy volunteers ingested 120 mg EGb 761 or placebo daily for 3 months. After 3 months the groups
switched to the other test substance for the next 3 months. In the placebo cycles, AA-stimulated
thromboxane B 2 (TXB 2 ) production was 25811337 pg/106 platelets (range 897-5485) compared to
1668992 pg/106 platelets (range 6-1668) in the EGb 761 cycles (p<0.005). Incubation of platelet-rich
plasma with EGb 761 (150 g/ml) completely inhibited platelet aggregation accompanied by inhibition
of TXB 2 synthesis in all subjects both in the placebo (<200 pg TXB 2 /106 platelets) and EGb 761 cycles
(<120 TXB 2 /106 platelets) (p<0.0001). These results support EGb 761-mediated inhibition of platelet
TXB 2 synthesis in vivo.
Dodge et al. (2008): In the primary analysis the overall and event specific proportion of subjects
who reported adverse events were compared between the Ginkgo biloba extract (GBE) and placebo
groups using Fisher exact test. There was no overall difference in adverse events reported by subjects
in the GBE group, compared to subjects in the placebo group (difference in proportions, p=0.44).
However, the GBE group had more stroke or TIA incidences (7 reports, 11.7%) compared with the
placebo group (0 report) (p=0.01, uncorrected for multiple comparisons). All strokes were nonhaemorrhagic infarcts except one case; the subject with haemorrhagic infarct continues to participate
in the study after the event. There were no deaths due to stroke. Four out of seven participants with
stroke incidence continued to participate in the study. There was no difference in the incidence of
haemorrhagic events such as gastrointestinal ulcer, epistaxis, or ecchymoses. Mortality was not
different between the groups (five subjects among each group). It was concluded that the increased
stroke risk will require further close scrutiny in other GBE prevention trials.
Reviews and meta-analyses:
Getov et al. (2007) performed the study by a literature search for safety profile assessment in
clinical studies examining the effect of the standardised extract EGb 761. Safety profile of Ginkgo
biloba products is rarely assessed in comparison with efficacy. Only five studies focus on product safety
(Kanowski 1997, Le Bars 1997, Hofferberth 1994, 1989 and Schmidt 1991). Out of them, four studies
state the product is well tolerated and one study, in addition, proves its safety. Safety assessment
indicates the following adverse drug reactions (ADR): hypersensitivity reactions, skin reactions
(erythema, edema, and itching), and gastrointestinal disorders including abdominal pain, diarrhea,
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 114/120
nausea and headache. From safety requirements point of view, the ADRs could be characterised as
predominantly mild, with low occurrence, and presenting permissible (acceptable) risk.
IQWiG (2008): Overall, the results on adverse drug effects were inconsistent. With regard to serious
adverse events and overall adverse events, there was no indication of harm caused by ginkgo.
However, evidence was available that with ginkgo, more patients discontinued the study due to
adverse events than with placebo.
The purpose of the study by Kellermann et al. (2011) was to undertake a systematic review and
meta-analysis of 18 randomised controlled trials to assess the impact of Ginkgo biloba leaf extract as
single therapy compared with placebo on risk of bleeding, determined by assessing parameters of
haemostasis.
Forest plots of meta-analysis for the outcome parameters of haemostasis
Blood flow:
Blood viscosity:
Fibrinogen concentration:
Page 115/120
Prothrombin time:
Spontaneous bleeding of the nose, ecchymosis and haemorrhoidal bleeding (Bent et al.
2005)
Postoperative bleeding (Bebbington et al. 2005, Yagmur et al. 2005, Fessenden et al.
2001, Norred and Finlayson 2000)
The majority of the used preparations in the above mentioned case reports were of unknown origin
and quality. These were over-the-counter ginkgo products marketed in the American and UK markets.
The monograph relevant preparation was only involved in two of the case reports. Since these reports
Page 116/120
were compiled under conditions of routine medical care and not under the controlled conditions of a
clinical trial, they often lacked substantial background information and, in particular, central
coagulation parameters were either not available at all, or were measured under non-standardised
conditions. The technical difficulties commonly associated with the standardisation of bleeding time and
coagulation parameter measurement are well known.
In the absence of relevant data from controlled studies, an evaluation of case reports for evidence of a
causal association between ginkgo use and bleeding includes different causality assessment elements.
Besides timing of event relative to ginkgo exposure, the presence of other factors that might have
caused bleeding, dechallenge and rechallenge are widely accepted elements to establish causality.
In 10 of the 13 cases providing information about duration of use exist. It was reported that ginkgo
was taken for more than 6 months before the bleeding event. Two cases, one with hyphema and one
with cerebral haemorrhage, had used ginkgo for 2 months. In the other case of hyphema, ginkgo was
used for only 1 week.
In addition, other risk factors were reported in most cases that could have caused the bleeding event.
The most common risk factor was age. In 13 of the 16 cases patients were aged 59-78. Another risk
factor was coadministration of medications known to increase the risk of bleeding (aspirin, warfarin,
ibuprofen or vitamin E). Other risk factors for bleeding included a fall or an operation.
Only 8 of the 16 cases specifically noted that ginkgo was stopped. None of these cases had recurrent
bleeding by a follow-up time of 10 days to 4 years. Only one case reintroduced ginkgo after the
bleeding event. The measured bleeding time after reintroducing ginkgo increased to >15 min (normal
range 2.5 to 9.5).
Some of the authors of these case reports therefore admitted that a causal relationship between
Ginkgo biloba and the haemorrhagic complications could not be established definitively; albeit, it could
not be excluded as well. For most of the case reports a possible causal association between ginkgo and
bleeding events was suggested.
According to the pharmacovigilance database of the BfArM 74 cases of haemorrhage during the
intake of Ginkgo biloba medicinal products are reported in Germany (June 20, 2012). It should be keep
in mind that these are suspected cases of adverse events and a causal link on an individual basis is not
certainly proved. The specific location of bleeding incidences of reported adverse events (with 5 or
more than 5 cases mentioned) are as followed: epistaxis, cerebral haemorrhage, gastrointestinal
haemorrhage, gastric ulcer haemorrhage, haematoma, eye haemorrhage, melaena and decreased
haemoglobin value. Included in the 74 reported adverse events are five cases of deaths. The deceased
aged between 71 and 76 (one is unknown), where age is the most common risk factor that might have
caused bleeding in these patients. Another risk factor known to increase the risk of bleeding was that
four patients took at least one additional medicinal product that also has an influence on the
characteristics of blood (anticoagulants in 4 out of 5 cases).
Kupiec and Raj (2005) presented a case report of a 55-year-old male who suffered a fatal
breakthrough seizure, loss of consciousness and death, with no evidence of non-compliance with his
anticonvulant medications. The autopsy report revealed subtherapeutic serum levels for both ingested
anticonvulsants (Depakote and Dilantin). Concomitant with his prescribed medications, the decedent
was also self-medicating with a cornucopia of herbal supplements and nutraceuticals a year prior to his
death, prominent among which was Ginkgo biloba. Herbal drug interactions of Ginkgo biloba and CYPs
metabolised drugs are known. Both anticonvulants are metabolised by CYP2C9 and CYP2C19. The
proposed inducing effect of Ginkgo biloba on CYP2C19 activity could be a plausible explanation for the
subtherapeutic levels of the two anticonvulsants, whereas these fluctuations in the concentrations
could not be definitively attributed to the herb-drug interactions. However, without a qualifying lable or
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 117/120
a standardised quality control process, use of some nutriceutical products may prove to have
hazardous consequences in individuals with a history of convulsive disorders.
Page 118/120
6. Overall conclusions
A specified preparation of Ginkgo biloba fulfils the requirements of well-established use. There are
different clinical studies which demonstrate benefits of Ginkgo biloba in patients with mild dementia
especially above the age of 50 years, which are displayed in the indication: Herbal medicinal product
for the improvement of (age-associated) cognitive impairment and of quality of life in mild dementia.
The results are supported by meta-analysis of several clinical trials. Overall, there is a reasonable
safety profile of Ginkgo biloba preparations. With respect to side effects bleeding events have been
observed. This signal can be adequately addressed by appropriate labelling. Existing data on
interactions are as well adequately addressed in the respective section. The evaluation of the NTP
Assessment report on Ginkgo biloba L., folium
EMA/HMPC/321095/2012
Page 119/120
technical report, which was addressing toxicological concerns, led to the conclusion that at present
there is no proof for an increased cancer risk identified for patients taking Ginkgo folium medicinal
products at their approved posology. Overall the benefit-risk-ratio is considered positive.
Criteria for a traditional use are fulfilled for a powder usually administered in a capsule. The discussion
finally concluded that the following indication reflects the traditional use and complies with the
requirements of traditional herbal medicinal products: Traditional herbal medicinal product for the
relief of heaviness of legs and the sensation of cold hands and feet associated with minor circulatory
disorders, after serious conditions have been excluded by a medical doctor. All safety relevant
labelling for traditional use are based on data reported for extracts of Ginkgo biloba on the wellestablished use part of the monograph. It cannot be excluded that they may occur with the powder. A
Community list entry was not established due to lack of specific data on genotoxicity. Moreover, it is
questionable, if the safety profile of Ginkgo in general is suitable to establish a Community list entry.
Annex
List of references
Page 120/120